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Note 
I feel that it is important to recognize that because my thesis inherently revolves around               
individuals with biological reproductive capabilities that are consistent with their performed           
gender, this work necessarily focuses on cisgendered people. Moreover, I occasionally use the             
terms “woman” and “female,” and “man” and “male” interchangeably, though I try to be              
intentional about when I use each term, as biology and social identity are not one and the same. 
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Introduction 
The introduction of effective family planning in the second half of the 20th century 
brought on profound and beneficial social changes, as well as significant improvements in public 
health outcomes. The Centers for Disease Control and Prevention (CDC) named family planning, 
including access to modern contraception, one of the 10 great public health achievements of the 
20th century (1999). For evident reasons, women have long been the primary targets in the 
promotion of family planning, both in developed and developing countries. Effective 
contraceptive use has allowed women to space out and limit pregnancies to best fit their personal 
desires and financial resources. The freedom to effectively and independently control their own 
fertility has proven crucial to women’s economic and social advancement, and continues to have 
a positive impact on education and workforce participation, as well as on subsequent outcomes 
related to income, family stability, mental health and happiness, and children’s well-being.  
However, despite the vast expansion of contraceptive access and choice, there continues 
to be a global unmet need for contraception. According to a 2015 United Nations report, 216 
million married women worldwide want to delay or avoid pregnancy but are not using 
contraception. In the United States alone, there are 61 million women of reproductive age 
(15–44), of whom about 43 million, or 70%, are at risk of unintended pregnancy. That is, they 
are sexually active and do not want to become pregnant, but could become pregnant if they and 
their partners fail to use a contraceptive method correctly and consistently (Guttmacher Institute, 
2018). Currently about 85 million unintended pregnancies occur annually worldwide, including 
approximately half of all pregnancies in the U.S., and up to one quarter of pregnancies 
worldwide end in induced abortion (Sedgh, Singh, & Hussain, 2014; Allen, Kaunitz, & Hickey, 
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2016; Guttmacher Institute, n.d.). Lowering the number of unintended pregnancies would 
improve quality of life for millions of adults, reduce abortion rates, and trim health care 
expenditures. This unmet need stems in part from issues of cost and accessibility, and in part 
from the fact that currently available female methods are not adequate for all women. Many 
methods entail significant side effects and associated health risks, have higher failure rates in 
actual use, may make demands on users that cannot in fact be met, or are inconsistent with the 
mores, practices, and deep-seated preferences of users or their sexual partners (Sedgh, Ashford, 
& Hussain, n.d.; National Research Council and Institute of Medicine, 1990). In order to begin to 
alleviate this issue, alternative solutions must be explored, and a large untapped user population 
must be recognized. 
Globally, men tend to take a back seat in matters of contraception, so that the burden of 
birth control falls primarily on women. This disparity is based upon prevailing assumptions 
surrounding contraceptive responsibility and interests in family planning. However, increasing 
evidence suggests that new generations of men are willing to participate more actively in fertility 
control. While recognizing that reproductive issues more directly and profoundly impact the 
lives of women than men, men should have the ability to “demonstrate their identification with 
reproductive rights by taking responsibility for their own reproductive health and fertility 
control” (Solinger, 2013, p. 142).With this in mind, greater efforts to acknowledge and expand 
men’s involvement in contraceptive decisions and behavior must be made. Broadening method 
choice to allow men and women the option to share family planning responsibilities has the 
potential to satisfy crucial individual and societal needs by helping to fill the current unmet 
 
 
 
         6  
contraceptive need, and advancing gender equality by rectifying the current imbalance of 
contraceptive burden.  
The description of contraception as a burden aims not to detract from its obvious virtues, 
but to reflect the various economic, emotional, psychological, and physical costs that women 
routinely tolerate for the sake of its benefits. Despite this reality, dissatisfaction with existing 
female methods remains a minimized issue in health care services and biomedical research, and 
is generally obscured by the sheer quantity of options. In the decades since the advent of the oral 
contraceptive pill in 1960, the number of reversible methods for women has expanded to include 
a wide variety of options, including intrauterine devices (IUDs), shots, patches, rings, implants, 
diaphragms, sponges, and cervical caps. Meanwhile, men continue to rely on the same few 
contraceptive options: vasectomy, condoms, and coitus interruptus, or withdrawal. Vasectomies, 
while highly effective, lack appeal due to their surgical nature, and are considered largely 
irreversible. Condoms, while important for protection against sexually transmitted infections, 
have limited user efficacy, with a failure rate between 13-18% with typical use, a statistic that 
indicates the percentage of women who will become pregnant within a year of method use 
(CDC, 2018; Guttmacher Institute, 2018; U.S. Department of Health and Human Services (HHS) 
Office on Women’s Health, n.d.). Withdrawal, a lifestyle method rather than a technology, 
proves even less reliable with a failure rate of approximately 22% (CDC, n.d.). The significant 
drawbacks of existing methods reflect the failure of male contraceptive options to rival those 
available to women. 
This discrepancy has long been recognized, yet little has changed in the field of male 
contraception for more than a century. Although research has been ongoing in many parts of the 
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world since the 1970s or earlier, commercial product development has stalled. One researcher 
lamented, “The joke in the field is: The male pill's been five to 10 years away for the last 30 
years” (Watkins, 2012). Indeed, it is astonishing that after more than half a century of 
investigation, and despite huge medical advancements in many other fields, no new technology 
has emerged. The slow and seemingly fruitless trajectory of male contraceptive development 
thus requires a deeper examination of the social, cultural, political, and economic contexts in 
which scientific knowledge has been produced and technological artifacts have been created.  
We tend to view technological entities merely as objects of use, often failing to ​realize 
that choices about our social order are fixed in the material we choose to create. Political theorist 
Langdon Winner suggests that we ask ourselves, “As we ‘make things work,’ what kind of world 
are we making?” He urges us to “pay attention not only to the making of physical instruments 
and processes, although that certainly remains important, but also to the production of 
psychological, social, and political conditions as a part of any significant technical change” 
(1986, p. 17).​ ​In order to do so, we must understand technology not only in terms of its physical 
function but in terms of social institutions, behaviors, symbolic means, formation of identities, 
and culturally rooted belief systems. We cannot think about technology only in the context of our 
individual interactions with artifacts, but also in the way that their design and arrangement build 
order in the world. 
Technology does not merely aid human activity, but fundamentally shapes human 
activity and its meaning (Winner, 1986). It has the ability to update or reinforce pre-existing 
patterns, or to enable entirely new activities. It can moreover embody specific forms of power 
and organization. It can be ​“centralized or decentralized, egalitarian or inegalitarian, repressive 
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or liberating” (Winner, 1986, p. 29). The introduction of female birth control as contraceptive 
technology, ​in this case,​ was indisputably liberating and equalizing for women in myriad ways. 
For this reason, male birth control should not be considered a replacement but an added option. 
The possibility of a new male contraceptive should in no way detract from the monumentality of 
women’s access to birth control, which remains a vital public health priority. Nevertheless, the 
continued imbalance of methods available to men and women has complicated the role of 
contraceptive technology in society. While female contraception has in many ways liberated 
womankind, the absence of a comparable male option has simultaneously contributed to the 
formation of repressive and inegalitarian systems of social organization in which women are 
regularly and automatically expected to bear this burden, regardless of the personal costs. 
Indeed, the absence of technology proves just as significant as its presence. ​Professor and 
activist Betsy Hartmann wrote: 
“It is no accident that at the end of the twentieth century billions of dollars are spent 
every year on weapons of destruction and luxury goods, while technologies that could 
dramatically improve people’s lives—nonpolluting energy sources, sustainable 
agricultural systems, basic health and sanitation measures--receive minimal funding at 
best. Those who hold the reins of power exercise power over technological choice.” 
(Hartmann, 1995, p. 173).  
The relationship between humans and technology is a reciprocal one. Technological innovations 
are not neutral—they embody the values of their creators. ​They are the products of social 
processes and social choices, and c​ontraceptive technology is no exception. The continued 
absence of male birth control requires an examination of why some technologies succeed while 
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others fail, and illustrates how certain social issues and scientific aims are prioritized while 
others are neglected or actively silenced. In addition to examining the ways in which 
contraceptive technology shapes human activity and builds order in the world, we must examine 
the ways in which human actions and agendas shape the production, design, and distribution of 
technology. These processes are negotiated by relevant stakeholders and social groups, shaped 
by their interests, and driven by the relative power they possess. Those involved directly or 
indirectly in the pursuit of male birth control include researchers, clinicians, policy-makers, 
pharmaceutical industry leaders, nonprofit organizations, government agencies, potential users, 
and their partners, each with their own interpretations of what this technology would mean and 
what it could offer. 
In chapter one, I use a historical lens to identify the confluence of social and scientific 
conditions that led to the development of the famed pill and the definitive shaping of 
contraception as a female arena. In chapter two, I examine how shifting or enduring norms in 
gender roles influence men’s perceptions of contraceptive participation, responsibility, and 
acceptability. I use this analysis to gauge consumer interest and to evaluate the sociocultural 
feasibility of the male contraceptive objective. In chapter three, I discuss the technical feasibility 
of this goal, give an overview of previous and current scientific endeavors, and challenge the 
validity of the argument that biological limitations are the root of stagnation in this field of 
research. In chapter four, I explain the failure of promising research to be translated into a 
commercial product by identifying the difficulties of bringing new technology from laboratory to 
market. I identify the lack of pharmaceutical industry funding and the stringency of federal 
regulation as delaying the process, and discuss whether these factors reflect good market sense 
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and necessary safeguards or a continued gender bias in biomedical innovation. To accomplish 
this, I compare current events to the history of female contraceptive development and use.  
I argue that given evidence of growing consumer interest and evolving sociocultural 
norms, as well as encouraging scientific work and abundant prospects for continued research, the 
greatest obstacles to male contraceptive development lie in the barriers to bringing promising 
technologies to market. I argue that as medicine has become increasingly commercialized, those 
with the greatest resources and influence have prioritized profit over public need. I moreover 
assert that while high standards and regulatory caution are justified given past errors in 
pharmaceutical development, marketing, and regulation, there exists a a fundamental, deeply 
ingrained double standard in our society’s perception and treatment of the reproductive 
well-being of men and women. For these reasons, male contraception as an objective has lacked 
the attention, legitimacy, momentum, and resources needed to be brought to fruition.  
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Chapter 1: The Shaping of Contraception as a Female Arena  
The Rise of Reproductive Medicine and Women as Objects of Medical Intervention 
In order to envision a society in which the use of a new male contraceptive method could 
be normalized, we must first consider how and why contraception came to be recognized as an 
overwhelmingly female domain. This process began significantly before the rise of the pill, 
before even the recognition of contraception as a legitimate field of study. Female reproductive 
bodies have long been ​perceived as the natural objects of intervention (Oudshoorn, 2003). The 
field of gynecology was first established in the late 19th century as a new specialty in the 
biomedical sciences, the growth of which was not paralleled by the establishment of a 
complementary male-focused speciality for years to come. With the emergence of gynecology, 
women came to be identified as a “special group of patients” (Oudshoorn, 2003, p. 5). As 
reproductive sciences emerged in the beginning of the 20th century, concurrent progress in the 
field of hormone research led to studies of reproductive physiology (Watkins, 1998). With the 
development of sex endocrinology, or the study of sex hormones, in the 1930s, biologists for the 
first time “solved the riddle of the female reproductive cycle,” demonstrating the effects of 
changes in hormonal levels on the physiology of reproductive structures in ways that proved 
fundamental to the subsequent development of hormonal contraception (Watkins, 1998, p. 22). 
With the emergence of these new disciplines, the field of medicine was newly provided with the 
tools to intervene in processes previously considered inaccessible and to transgress boundaries 
long thought to be natural. Furthermore, the existence of gynecology allowed this new science to 
focus almost exclusively on the female body (Oudshoorn, 2003, p. 5).  
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As the physiological processes of reproduction were brought into the domain of medical 
intervention for the first time, the female body became institutionalized in reproductive research 
and treatment. Andrology, a field devoted to the study and medical treatment of male 
reproductive bodies, did not emerge as a clinical science until the middle of the 20th century. 
The term was first coined in 1951 by a German gynecologist, but it was not until the last quarter 
of the century that the term gained real acceptance as an independent specialty, and the field 
remains marginal in comparison to that of gynecology, with reproductive scientists noting that 
the number of investigators interested in the former as opposed to the latter is “very small” 
(Basu, 2011; Oudshoorn, 2000, p. 131). The trajectory of reproductive science and medicine in 
the 20th century had two key consequences. First, the existence of obstetrical and gynecological 
clinics and the contrasting nonexistence of andrological clinics played a key role in the 
development of knowledge about human fertility (Clarke, 2000). Thus, when fertility control 
became an area of technological interest, scientists’ knowledge of the female reproductive cycle 
provided more hints about rational approaches to contraception than did their knowledge of the 
male process. Second, as women increasingly became the focus of medical intervention, those 
with the power to intervene were overwhelmingly male: when the pill emerged in the 1960s, the 
overwhelming majority of American obstetricians and gynecologists were men (Djerassi, 1994). 
The emergence of female birth control methods thus coincided with changing attitudes within the 
medical profession that encouraged the medical management of reproductive health and 
increased male doctors’ power over women’s bodies (Tone, 2001). 
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The Pursuit of a Female Contraceptive 
In the 1950s, ​the state of scientific knowledge, the passion and convictions of several key 
figures, and the public’s faith in the ability of science and technology to solve social problems 
dictated the path of contraceptive research toward a female method in the mid-20th century​. In 
the years following World War II, overpopulation became a growing public health concern 
(Oudshoorn, 2003; Gutmann, 2007). This era also saw the peak of American enthusiasm for 
technological development following the introduction of a succession of wonder drugs, including 
antibiotics, tranquilizers, and steroids. At this point in time, the confidence in and relevance of 
the contraceptive cause to multiple social groups provided the necessary impetus to push forward 
the agenda. ​The search for female birth control was pioneered primarily by activist and sex 
educator Margaret Sanger​. Sanger’s cause aligned advantageously with the social goals of other 
contemporary groups, including the Population Council, a nonprofit, private organization with an 
international focus on population control, as well as members of the eugenics movement. Sanger 
sought woman-controlled contraception to enhance women’s sexual autonomy and to secure the 
rights and wellbeing of individual women. Meanwhile, population control advocates targeted 
women because “it is women who bear children and therefore women who, in their logics, 
should be controlled” (Clarke, 2000, p. 43). These goals worked in complementary fashion such 
that the terms “family planning,” “birth control,” and “population control” were used 
interchangeably in the 1950s and ’60s. Therefore, when this project commenced, it elicited 
enough momentum and support to be brought to fruition (Tone, 2001; Watkins, 1998).  
As these objectives came to the forefront of science in this era, a number of intellectual, 
economic, and sociocultural factors “conspired to preclude the development of a male 
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contraceptive” (Watkins, 1998, p. 20). The first of these factors were the interests and goals of 
Sanger and suffragist and millionaire heiress ​Katherine McCormick, who​ ​bankrolled Sanger’s 
crusade. ​At the time, contraceptive research received no funding from pharmaceutical firms or 
from the government, and Planned Parenthood, the organization Sanger founded, lacked the 
financial resources to do so (May, 2010). Both Sanger and McCormick insisted on a method that 
could be controlled entirely by women, feeling that birth control should be their right and 
responsibility (Watkins, 1998). Sanger dreamed of female empowerment through 
women-oriented technologies, and believed that male-oriented technologies compromised this 
objective by placing women’s procreative destiny in the hands of men (Tone, 2001). Sanger 
declared that “science must make woman the owner, the mistress of herself. Science, the only 
possible savior of mankind, must put it in the power of woman to decide for herself whether she 
will or will not become a mother” (May, 2010, p. 25). Consequently, this area received all of 
Sanger’s attention and all of McCormick’s financial backing. 
Sanger required the scientific know-how and manpower to complete the project, and her 
call for scientists to take on this challenge was answered by Gregory Pincus, a biologist with 
relevant experience in both reproductive science and hormone research (Watkins, 1998). Aided 
by prior breakthroughs in steroid chemistry, ​“spurred by one determined feminist and sustained 
by another,” Pincus used his professional experience to create a scientifically feasible and 
culturally appealing solution to the issue of family planning: the oral hormonal contraceptive 
(Watkins, 1998, p. 21). Once he had ​proven his success in developing the pill, the 
pharmaceutical company G.D. Searle & Co. made a serious fiscal commitment to the project 
(​Watkins, 1998, ​p. 25). Thus, all of the necessary pieces fell into place: “Chemists had figured 
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out how to synthesize a more powerful analog of natural progesterone, and at least one company 
hoped to capitalize on the market. Pincus was both willing and eager to act as head scientist of 
the venture. McCormick contributed the necessary funds, and both she and Sanger provided the 
motivation for the project to move forward” (Watkins, 1998).  
Pincus had originally been investigating hormonal contraception for men as well, yet that 
research never came to fruition once the female version was found to be successful. A ​focus on 
men provided several scientific obstacles. First was a matter of stigma: work on male 
contraceptives was a marginalized activity in the already marginalized reproductive sciences and 
contraceptive development worlds (Clarke, 2000). As R.J. Ericsson, an early pioneer in male 
reproductive research, complained, “Male contraceptive research has a dismal past. It is almost 
an illegitimate specialty within reproductive biology. For the most part, the brightest workers 
avoid it, and those who do work in the area are looked as rather strange fellows” (Hartmann, 
1995, p. 179). Second was a matter of practicality: the task of inactivating the millions of sperm 
produced each day appeared daunting. This approach also presented more of a clinical challenge 
to scientists and clinicians, who could find a readier supply of women as guinea pigs for 
contraceptive research than of men: “women can be easily assembled for clinical studies through 
their association with Planned Parenthood clinics and individual obstetricians or gynecologists; 
there exists no simple mechanism for assembling similar groups of males for clinical 
experimentation” (Djerassi, 1994, p. 45). Third was a matter of demand: men at the time 
appeared to be averse to the idea of physical control of their reproductive systems. Pincus 
identified this contrast: “Male volunteers for fertility control studies may be numbered in the low 
hundreds, whereas women have volunteered for similar studies by the thousands….He has 
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psychological aversions to experimenting with sexual functions….Perhaps experimental studies 
of fertility control in men should be preceded by a thorough investigation of male attitudes” 
(Watkins, 1965, p. 194). ​Scientists involved in contraceptive research at the time justified the 
relative lack of attention to men by characterizing men’s psychological frailty as a significant 
impediment to male contraceptive development (Tone, 2001). According to a professor of 
obstetrics and gynecology at the Harvard Medical School, man’s “virility, sense of maleness, 
even his self-esteem are more closely allied to the sexual act than that of a woman...any method 
of contraception that diminished sperm count would create psychological problems for many 
men, leading to ego loss and impotence” (Kistner, 1969, p. 68). ​Consequently, a combination of 
scientific, social and cultural forces, as well as the contributions of several key figures, acted in 
concert to drive contraceptive research in the direction of a hormonal pill for women in the 
mid-20th century. 
 
Contraception and Control 
Women’s enduring pursuit of a means to independently prevent pregnancy during the 
20th century reflected the burden they had borne for centuries when their wishes about when and 
how many children to have were overridden or ignored by their male partners. The history of 
women’s efforts to prevent unwanted pregnancies is riddled with strange and extreme measures 
that were often neither safe nor effective. As far back as 1850 B.C.E., recipes for contraceptive 
pessaries in ancient Egypt included honey, sodium carbonate, and crocodile dung. Around 900 
B.C.E., Chinese women drank mercury to control their fertility, which often resulted in sterility 
or death. During the Middle Ages in Europe, women were advised to wear the testicles of a 
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weasel on their thighs or hang its amputated foot from around their necks (Planned Parenthood, 
2015b). ​In the United States in the late 19th century IUDs became popular, yet many doctors 
refused to insert them unless there was “legitimate medical need,” and at the turn of the century 
IUDs were the most painful and medically dangerous birth control method. They were bulky, 
large, and difficult to insert (Tone, 2001 p. 75).​ At a time when contraception remained largely 
illegal, such methods were neither easily accessible nor easily endured. 
In the 1920s and ’30s, a “grey” market for contraceptives flourished in the U.S. through 
the use of legal euphemisms. Devices and chemicals known to have contraceptive abilities such 
as ​such as douching syringes, antiseptic tampons, sponges, suppositories, and solutions ​were 
innocuously marketed as “feminine hygiene products​.” Before the Depression, condoms were the 
most popular commercial contraceptive in the U.S. By the late 1930s, sales of female 
contraceptive products outnumbered those of condoms five to one. ​Throughout this era, 
“contraceptives ​that would be almost 100 percent effective were unfathomable,”​ and t​he dangers 
and deficiencies of these products were well known in the health community (Tone, 2001, p. 71). 
Manufacturers “preyed on and compounded women’s fears of pregnancy to reap higher profits,” 
and “manipulated women’s anxieties to hawk goods that were useless as contraceptives and 
dangerous to women’s health” (Tone, 2001, p. 157). Within this profitable and unfettered trade, 
desperate women became “the market’s most reliable and, by extension, most exploited 
customers” (Tone, 1997, p. 213). By 1940, the commercial antiseptic douche had become the 
most popular birth control method in the country, and would remain the leading contraceptive 
until the introduction of the pill in 1960. Lysol, the most popular brand, did not prevent 
pregnancy, and contained ingredients which, when used in too high concentrations, caused 
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severe inflammation, burning, and even death (Tone, 2001).​ Thus, for centuries, many attempts 
at fertility control relied on folklore or faulty science, born out of hope and desperation. By 
contrast, the hormonal contraceptive technology developed in the 1950s was based upon an 
understanding of the physiology and biochemistry of reproduction. The advent of the pill in 1960 
gave women a highly reliable way to control their own fertility for the first time in history.  
Prior to 1960 and the emergence of modern, female-oriented birth control technology, 
other primary available methods—condoms, vasectomy, and withdrawal—were male-oriented. 
Though the rubber condom was first introduced in the 1850s, rudimentary versions of the 
condom date back thousands of years. Condoms transformed in efficacy over time with the 
invention of latex in the 1920s, design improvements in the 1950s, and the introduction of 
alternative materials in the 1990s (Khan et al., 2013). The use of vasectomy for human 
sterilization as part of eugenics programs dates back to the late 1890s, but the procedure came to 
be regarded as a method of consensual birth control during World War II (Leavesley, 1980). In 
general, because neither men nor women had many options prior to the pill, “no stabilized 
conventions existed concerning the relationships between gender identities and contraceptive 
use,” despite the fact that those most reliable and least risky were male-controlled (Oudshoorn, 
2003, p. 13). However, with the so-called “contraceptive revolution” of the 20th century 
primarily restricted to female methods, these relationships began to solidify (Saetnan, 2000).  
The availability of higher-tech, more effective contraceptives for women qualitatively 
and quantitatively altered the set of alternatives from which couples could make their selections, 
effectively curtailing the decision-making process and altering the balance of male-female 
involvement in contraceptive use. Furthermore, contraceptive efforts before the pill were not 
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only often male-controlled, but generally had to be used at the time of intercourse or were related 
to the timing of intercourse. The advent of the pill, a method independent of intercourse that 
could be used without the knowledge, cooperation, or control of male partners irrevocably 
changed the link between sexuality and contraception and enabled greater user autonomy. The 
implementation and use of female hormonal contraceptives demonstrated that ​“as technologies 
are being built and put to use, significant alterations in patterns of human activity and human 
institutions are taking place” (Winner, 1986, p. 11).​ While the pill was liberating and 
empowering for women, giving them revolutionary control over their bodies and sexual lives, it 
simultaneously solidified contraception as a female burden and communicated to future 
generations of men that birth control is a responsibility outside their domain. 
 
A Revolutionary Technology 
The uniquely female desire for better fertility control was demonstrated by the rapid and 
widespread acceptance of the pill in the early 1960s. Within five years of approval, the pill had 
become the most popular form of birth control in the United States. Women rushed to their 
doctors actively requesting the pill, and b​y 1965, 6.5 million married women and hundreds of 
thousands of unmarried women had obtained prescriptions for oral contraceptives​ (Watkins, 
1998). Since then, access to modern birth control has been revolutionary for women. The 
unprecedented ability to plan and space the birth of children has allowed them to take advantage 
of social, educational, and professional opportunities that unexpected pregnancies precluded, 
opportunities to which men already had greater access simply by virtue of being men. As Clare 
Boothe Luce, a renowned journalist, politician and playwright, wrote in 1969, “modern woman 
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is at last free, as a man is free, to dispose of her own body, to earn her living, to pursue the 
improvement of her mind, to try a successful career” (Marks, 2001, p. 183). Access to birth 
control has been tied to increased college enrollment, increases in the proportion of women in 
skilled careers, and increased earning power and narrowing of the gender gap in pay (Sonfield et 
al., 2013; Planned Parenthood, 2015a). By contrast, men’s control over their own bodies, careers, 
and lives has never been at stake in the same way. For this reason, one potential obstacle to 
attracting men to new contraceptive options is that male birth control is unlikely to substantially 
improve a man’s quality of life in the same way that it has for women.  
 
The Male Objective 
Male contraceptive efforts first emerged in the 1970s, catalyzed by two powerful social 
forces: the recognition of a dire need for population control in the developing world, and the 
feminist movement in the Western industrialized world advocating for gender equality 
(Oudshoorn, 2003). With regard to the former, the problem of overpopulation motivated and 
legitimized research into a male contraceptive just as it had done for the female pill (May, 2010). 
One scientist reasoned that “because of the immensity and seriousness of human population 
growth every avenue should continue to be explored and we should be unwise to neglect the 
male approach” (Oudshoorn, 2003, p. 19). This approach was advocated largely by government 
figures in China and India. Around the same time, women’s health advocates in the U.S. 
vocalized the need to put men on the contraceptive agenda following criticisms of the female 
contraceptive pill as its health risks were publicized. The impetus to transform the contraceptive 
status quo thus involved two types of discourse: a population control discourse, and an 
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emancipation discourse. The objective was sustained by the World Health Organization (WHO), 
which created a special task force and formed coalitions with governments and international 
agencies to spur the exploratory phases of research in male contraception, with clinical trials 
initiated in culturally diverse populations (Waites, 2003). Interestingly, the advocates for male 
contraceptive development were governments, public sector agencies, and feminists—not men 
themselves. As Roy Greep, a leading reproductive biologist in the U.S. described, “It is the need 
for male contraceptives and not the demand that is expanding exponentially (Oudshoorn, 2000). 
The inclusion of men in family planning policies and programs was more explicitly 
emphasized following the 1994 International Conference on Population and Development in 
Cairo and the UN’s Fourth World Conference on Women in Beijing in 1995. The official policy 
of government agencies and nonprofit organizations around the world has since been to 
encourage men’s involvement in birth control and safer sex practices in order the promote the 
rights of both women and men to regulate their fertility and have sexual relations free from fear 
of unwanted pregnancy (Gutmann, 2007; Solomon et al., 2007). However, despite the 
recognition of this issue, little headway has been made in significantly boosting men’s 
participation in this realm. 
 
The Forgotten 50% of Family Planning  
Historically, family planning efforts and reproductive health initiatives have typically 
focused on women. In public health and in academic studies, the terms “reproductive health” and 
“reproductive rights” generally refer to the health and rights of women. By contrast, issues of 
men’s reproductive health, when raised, usually refer to problems of the male organs or to 
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sexually transmitted infections. On the whole, the implicit assumption has been that men are 
neutral or begrudging partners in birth control utilization, “generally reluctant to share 
responsibility for preventing pregnancy from occuring during their few seconds of ejaculation,” 
and for this reason have received minimal attention (Gutmann, 2007, p. 100). The absence of 
men from the history of family planning is customary in academic disciplines that have 
pioneered research in reproductive health. Men are moreover remarkably missing from reports 
and teaching materials produced by governments, international health agencies, and family 
planning associations. Through these systematic omissions, the formation of a “female 
contraceptive culture” and the expectation that men will not participate in family planning have 
“become a self-fulfilling prophecy” (Gutmann, 2007, p. 116; p. 101). 
As the middlemen between producers and consumers, policymakers and service 
providers have played a key role in shaping fertility control as a woman’s domain by facilitating 
the integration of contraceptive technologies into society and enforcing their use. By determining 
an existing product’s availability to its potential user base, these “middlemen” are partially 
responsible for shaping user expectations and beliefs surrounding contraceptive use. Most 
obviously, policymakers and service providers control physical access to a method through 
public policy decisions, spread of information and education materials, and physical existence 
and location of services (Ringheim, 1993). Moreover, research in developing countries in 
particular has shown that the personal attitudes that service providers form through training can 
be passed on to clients, and can strongly influence perceptions of method acceptability 
(Ringheim, 1993). In general, the medical endorsement of female responsibility and innate male 
disinterest has encouraged the nearly exclusive targeting of women in professional guidance with 
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respect to birth control practices (Gutmann, 2007). Because women are systematically 
confronted by health personnel about birth control in ways that few men experience, unequal 
gender scripts are institutionally reinforced through these clinical encounters. 
That being said, it is increasingly being recognized that in both developed and developing 
countries, the prevailing family planning emphasis on women as the key figures in contraceptive 
decision making often excludes men in a way that imposed burdens on both men and women. 
Family planning services and clinics have been largely set up to serve women, and men may find 
it difficult to utilize them. A free general health, birth control, and sexuality counseling center for 
men that opened in the 1970s in San Francisco was believed by its staff to be the only one of its 
kind in the United States at the time, and highlights the need for changes within healthcare 
infrastructure to accommodate evolving social demands. The director of the clinic’s family 
planning program noted that she and other professionals had begun to notice more men 
accompanying their partners to family planning clinics, yet “there were no services provided for 
men—staff had more than enough to do taking care of women’s concerns—and there was no 
literature for them to read while they waited….The men got left sitting out by the elevator 
looking uncomfortable” (Stix, 1977). While the focus on women in the promotion of family 
planning and reproductive health is warranted for a number of reasons which have I already 
identified, the complete neglect of men’s roles in contraception represents a missed opportunity 
for the type of professional structure and guidance that could prove crucial to facilitating 
widespread use of a new male birth control method. Ringheim (1993) maintains that 
technological “failure should not be attributed to cultural bias until access to the method is 
observed to be easy, and appropriate education and information channels have been used to best 
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effect” (p. 88).  As demonstrated by the lack of access to services and educational information 
for men, as well as the physical absence of spaces for male involvement, it is evident that the 
idea that men have both a right and a responsibility to participate in family planning is not yet 
widely accepted.  
Changing the Dominant Cultural Narrative 
The idea that women were responsible for contraception thus became the dominant 
cultural narrative as it materialized in available technologies, social movements, and public 
objectives during the 20th century. As a result, t​he emphasis on women has become embedded in 
the institutional frameworks of science, medicine, and pharmaceuticals. The potential 
introduction of new male contraceptive thus relies not only on technological capabilities but 
intentional efforts to reshape contraception as a shared domain, one which facilitates the 
inclusion of men in these conversations and practices. In the face of such a task, we must ask 
whether men are open to such an opportunity. 
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Chapter 2: Gender Roles and The Consumer Perspective 
Gender Performance, Masculinity, and Contraceptive Norms 
Through the continual use of technologies, our individual habits, concepts of self, 
perceptions of the world, and social relationships, are powerfully molded, becoming so deeply 
ingrained that the “recurring patterns of life’s activity” that they facilitate “tend to become 
unconscious processes taken for granted” (Winner, 1986, p. 7). In the past century, the design 
and availability of contraceptive technologies have created a clear gender script, one which is 
now often taken for granted: responsibility for contraception and its risks is relegated primarily 
to women, not to men.  
As we consider possibilities for technological change, we must pay attention to the ways 
in which this gender script can be written. This task entails the mutual adjustment of 
technologies and user identities: “without a technology there are no users, and there are no users 
without a technology” (Oudshoorn, 2003, p. 12). Ever since the demand for new male 
contraceptives was articulated, people have wondered whether men would use such a method if 
it became available. Indeed, technologies only work if they are accepted by users and assimilated 
into society. Some have argued that ensuring the success of a finished product is a more likely 
challenge than its initial creation: “there is nothing inherently difficult about finding chemicals to 
inhibit male reproductive capacities…[but] will they use it? Will men, even in a pill-popping 
society like ours, take to taking the pill?” (May, 2010, p. 111). In the process of developing a 
new technology, designers must therefore anticipate the motives, preferences, tastes, and 
competencies of potential users, and must inscribe the views and tendencies of these users into 
the design of the new product (Oudshoorn, 2003). In recognizing the cultural embeddedness of 
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technology, we must acknowledge the role of cultural norms in shaping the behaviors and 
expectations of technology-users, and in the case of contraceptives, those norms as they pertain 
to gender roles.  
Considerations of the internalized expectations about what behaviors are appropriate for 
one’s gender are crucial to include in anticipating the needs and behaviors of technology-users. 
To examine the relationship between technology and gender identities, philosopher Judith 
Butler’s conceptualization of gender as performance provides a useful approach (1988). 
According to Butler and other feminist scholars, gender is not something we are, but rather 
something we do. In this view, gender is not predetermined or fixed, but rather reproduced 
through the “stylized repetition of acts” (p. 519). In other words, gender can be understood as 
“the mundane way in which bodily gestures, movements, and enactments of various kinds 
constitute the illusion of an abiding gendered self” (p. 519). Butler argues that a set of 
historically perpetuated and “punitively regulated cultural fictions” inscribe in us the belief in 
our own gender’s naturalness (p. 522). Because we support these fictions with the choices we 
make on a daily basis, the ways that we as individuals conduct ourselves in society yield 
opportunities to either reproduce existing meanings of gender or create new meanings.  
In the context of technological innovation, we must examine the ways in which 
technological artifacts and their uses play a role in stabilizing or destabilizing conventions of 
gender, and reinforcing or transforming gender performances. This being said, the relationship 
between technology and its users is a reciprocal one. Not only does the introduction of new 
technology have the potential to transform existing gender norms, but current gender norms play 
a pivotal role in determining what technology is produced in the first place, and further, whether 
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or not it will succeed. Thus, gender and technology can be viewed as mutually constitutive, or 
continually co-produced (Oudshoorn, 2003). In the case of contraceptive technology, the 
historical trajectory of technological development and the consequent socialization of 
reproductive behavior demonstrate the way in which technological innovation has the power to 
regulate and stabilize the gender performances to which Butler refers. As contraceptive 
responsibility became strongly aligned with traditional femininity, it simultaneously became 
excluded from the category of hegemonic masculinity. This notion has been perpetuated by 
subsequent efforts in contraceptive development, or rather the lack thereof. 
The development of new contraceptives for men thus requires the destabilization of 
conventional understandings and performances of masculinity. Oudshoorn (2003) asserts that 
“the construction of masculinities is at the forefront of the design” of socially and culturally 
feasible contraceptive technologies (p. 16). This recognition is crucial, for a commonly cited 
justification for the scarcity of male contraceptive methods is an apparent lack of consumer 
demand, based on the perception that men are not interested in or willing to use such technology. 
Grady et al. (2010) suggest that traditional beliefs about sex roles within a heterosexual 
relationship may be associated with the division of decision-making power into male and female 
“spheres of influence,” with contraception falling within the woman’s decision-making domain. 
Much of the perception that men will not be interested in added contraceptive options relies on 
ideas about appropriate gender enactments in the context of sex, and the idea that broaching an 
issue generally perceived as a “women’s topic” would violate traditional masculine sexual 
scripts. Sexual scripts, understood in psychology to be the cognitive schema for how sexual 
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interactions should unfold, are highly gendered, and mirror notions of traditional, hegemonic 
ideologies of femininity and masculinity (Masters, 2013).  
According to the traditional masculine sexual script, men’s bodies come preloaded with 
strong sexual urges that make them relatively unconcerned about risk and long-term 
consequences, tend to value sex more than relationships, and are more oriented toward sexual 
variety. The complementary traditional feminine sexual script suggests that women are less 
desiring, more concerned about risk, more relationship-oriented, and less interested in variety 
(Masters, 2016). Individuals typically subscribe to sex-role stereotypes and conform to the 
behavior dictated by them in order to affirm their own masculinity or femininity. Traits that are 
thought to conform to the stereotypical performance of masculinity include aggression, 
impulsivity, and phallic assertiveness in pursuit of sexual gratification, regardless of the 
consequences (Weinstein & Goebel, 1979). It has moreover been historically observed that men 
tend to be more pronatalist than women, though evidence is mixed with respect to this 
assumption, and modern data points to similarities in desired family size between men and 
women (Greene & Biddlecom, 2004; RamaRao et al., 2008).  
According to this portrayal of masculinity, there seems to be no place for the behaviors 
and attitudes required to assume greater contraceptive responsibility. Effective fertility control 
requires “patience, punctuality, tolerance of adverse effects, and responsible behavior” 
(Ringheim, 1996). In family planning efforts in many countries, it has been assumed that men 
have to be “thwarted from their preordained natural tendencies” (Gutmann, 2007, p. 113). One 
survey of 150 men in the San Francisco Bay Area demonstrated the relationship between 
stereotypically masculine characteristics and contraceptive behaviors and attitudes (Gough, 
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1979). The results of this study, which took into account reports from men’s spouses and 
interviewers, suggested that husbands who expressed doubts about using a male contraceptive 
pill were were seen by wives as forceful, dominant, and aggressive. They were more often 
characterized by interviewers as power-oriented, masculine in style and behavior, outspoken in 
giving advice and stating personal opinions, and moralistic in regard to values. By contrast, men 
who expressed greater willingness to use a male pill were less likely to show condescending 
behavior in relations with others, less dogmatic and less forceful in asserting beliefs and 
opinions, more open to change, more likely to appear to observers as introspective, and more 
attentive to the feelings and wishes of others. 
Evidently, the construction of new gender norms that would be more conducive to male 
contraceptives cannot be accomplished without devoting greater attention to current male 
ideologies surrounding reproductive responsibility. It has been suggested that placing 
contraceptive control almost exclusively in the hands of women, despite its obvious benefits to 
women, may have also had some drawbacks in its cultural implications (Darroch, 2000). As 
women gained control of contraception, men were distanced from method choice and use. While 
some were likely glad not to bear the weight of this responsibility, others may have felt excluded 
by women who saw fertility control as their sole prerogative. Either way, men have come to be 
regarded as “important economically but as typically uninvolved in fertility except to provide 
sperm and to stand in the way of contraceptive use” (Greene & Biddlecom, 2004, p. 7). With 
continuing patterns of disproportionate maternal responsibility for child rearing,“men are 
typically less connected to and less likely to take responsibility for the health and safety of 
fetuses and children” (Solinger, 2013, p. 141). Consequently, some men appear unaware of the 
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extent to which their personal well-being is depends upon the contraceptive responsibilities 
regularly taken on by women. A recent national survey found that more than half of American 
men don’t believe they have benefited personally from women having access to affordable birth 
control (PerryUndem, 2017). While this response was less common among younger age groups, 
this data suggests that a remaining obstacle to male involvement in contraception may be the 
failure for them to comprehend the full weight of women’s current contraceptive burden and its 
direct significance to them as men. 
This idea that fertility control is outside men’s realm of control has moreover been 
perpetuated by the systematic neglect of men in reproductive research, as demonstrated by the 
fact that demographic studies have tended to focus on women alone. Indeed, most analyses of the 
contraceptive decision making in which couples engage are based on the reports of only one 
partner, usually the woman (Grady et al., 2010; Greene & Biddlecom, 2004; Gold & Berger, 
1983). Because of their necessarily greater investment in fertility control, women’s knowledge 
and use of contraceptives has been seen as more relevant than male knowledge and use (Hulton 
& Falkingham, 1996). Greene & Biddlecom (2004) argue that despite the increasing inclusion of 
men in fertility research, studies of their reproductive attitudes and behaviors are still dominated 
by an overly “problem-oriented approach,” through which men are typically considered obstacles 
to women’s reproductive health rather than potential assets (p. 20). This approach fails to 
recognize the presence of a growing population of men who would be receptive to greater 
participation in contraceptive decisions and practices. 
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Perceptions of Responsibility 
Despite their relative neglect when compared to the vast body of female-focused 
research, a number of studies have been conducted to assess attitudes toward male contraceptive 
responsibility and interest in prospective technologies. These studies have, for the most part, 
pointed to changing perceptions of contraceptive roles as more egalitarian views gain 
prominence. Studies assessing theoretical interest in, as well as actual satisfaction with, 
experimental methods, have demonstrated that a majority of men believe contraception is a 
shared responsibility and a significant proportion in both developed and developing countries are 
receptive to assuming greater responsibility (Gough, 1979; WHO, 1982; Grady et al., 1996; 
Solomon et al., 2007; King et al., 2016; Ipsos, 2017; Male Contraceptive Initiative, 2019).  
Prior historical shifts in gender expectations have already demonstrated that such norms 
are transient and are shaped by their contemporary cultural context. At the onset of​ the 20th 
century, for example, the Victorian ethos of male self-control yielded to new ideas and 
institutions that “took male sexual activity for granted” as an uncontrollable force (Tone, 2001, 
p. 106). The turn of the 21st century has likewise been accompanied by ​a gradual and 
generational shift in commonly held beliefs regarding the duties of men in marriage, 
childbearing, and rearing. ​Sociologists ​Marsiglio and Menaghan predicted several decades ago 
that this liberalization of gender role expectations would likely facilitate increased male 
involvement in contraceptive responsibility (1987).  
Indeed, social scientists have noted a shift in men’s attitudes and perceptions of the 
impact of their roles and behavior on their partner’s health, particularly among young men 
(RamaRao et al., 2008; May, 2010). Merkh et al. (2009) concluded from an interview survey of 
 
 
 
         32  
young men in heterosexual relationships that although these men believed birth control decisions 
were ultimately a woman’s to make, they also viewed discussion of contraception as a potential 
relationship fortifier and a part of men’s contribution to pregnancy prevention, suggesting an 
interest in greater participation. According to a recent online survey conducted by the global 
market research firm Ipsos, nearly nine in ten Americans who identify as heterosexual believe 
that men and women have equal responsibility for birth control in a healthy relationship. The 
vast majority of respondents (89%) disagreed that a man who takes a male contraceptive is “less 
of a man.” However, a quarter of male respondents expressed concern that women would think 
less of them as men, and 29% stated that taking a male contraceptive would make them feel less 
masculine (2017). These results reflect that men’s theoretical willingness is likely to be 
complicated by certain concerns surrounding method acceptability, which I will discuss in the 
following section.  
Several studies have shown that more egalitarian sex-role beliefs are related to a greater 
likelihood of male pill usage (Marsiglio, 1985; Marsiglio and Menaghan, 1987). Moreover, 
demographic characteristics that have proven to be important predictors of a willingness to 
consider male contraceptive use include educational attainment,  income level, and current use of 
contraception. Men who are younger, more affluent, more highly educated, and more familiar 
with comparable female methods appear most likely to believe that men should bear some 
contraceptive responsibility in a relationship and more willing to use a hormonal contraceptive 
(Heinemann et al., 2005; Martin et al., 2000; Weinstein & Goebel, 1979; Ipsos, 2017). However, 
one caveat of many of these studies is that these men’s responses reflect ideology rather than true 
actions in their own relationships. That is, intention does not necessarily predict behavior. Thus, 
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men’s apparent willingness to use a male hormonal contraceptive should be interpreted 
cautiously, given the commonly observed discrepancy between beliefs, attitudes, and intentions 
with respect to actual behavior (Marsiglio & Menaghan, 1987; Ringheim, 1993).  
However, a number of men have lived up to their professed intentions through 
participation in any of the clinical trials that have intermittently emerged over the past several 
decades. Some simply consider themselves a more egalitarian breed of men, making statements 
such as: “I think men have been allowed to be lazy about all this”; “A man should have 50 per 
cent of the responsibility. This attitude is becoming more common. Women are not objects. 
They're the same as us. We're equals”; “My way of thinking is, once she’s taken the risk for a 
few years, I’ll take it...you halve the risk” (Ringheim, 1996, p. 87). Meanwhile, others seem 
motivated more by guilt than an intrinsic belief in equality. Ringheim (1996) interviewed one 
man whose clinical involvement was born out of a sense of obligation to relieve his partner from 
an evident burden:  
“Quite honestly, I never would have volunteered if my wife hadn't complained. My motto 
is: ‘If it isn't broken, don't fix it.’ I think most men are only too happy to have women use 
contraception. We know they have problems sometimes. Why would we want to share in 
that?” (p. 86) 
Some in committed relationships may feel the need to make up for their own powerlessness in 
the face of their partner’s suffering; the female partner of another trial participant noted that  
“He was very considerate when I used to have the migraines and I was banging my head 
against the bed. He said: “What can I do?” Just go away and leave me alone. I just want 
to die. He was always very sympathetic, but there was nothing he could do.” (p. 81)  
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For men who express a willingness to take on greater contraceptive responsibility in preliminary 
studies, the motivations for doing so appear to vary, as evidenced by these interview samples. 
 
Perceptions of Acceptability 
In addition to perceptions of responsibility, acceptability plays a significant role in 
determining the likelihood of men’s utilization of a new contraceptive method. Acceptability of a 
contraceptive method refers to how well, given existing choices, the method meets user 
preferences. Even if men theoretically hold egalitarian views of sex roles and agree that women 
should not bear the burden of contraception alone, their use of a technology in practice will be 
based on the acceptability of the method.  
King et al. (2016) discuss the use of the health belief model (HBM), a psychological 
model that can be used to predict contraceptive behavior, and which provides a useful framework 
for anticipating men’s attitudes toward a potential new male contraceptive method. The HBM is 
comprised of five primary constructs: perceived susceptibility, severity, benefits, barriers, and 
self-efficacy. The model posits that to be motivated to use contraception, an individual must 
consider himself to be susceptible to pregnancy (perceived susceptibility), believe that the 
pregnancy has potentially serious consequences (perceived severity), understand that the 
negative consequences of pregnancy are avoidable through effective use of contraception 
(perceived benefits), and believe that he is able to perform contraceptive behavior (self-efficacy). 
These factors are weighed against the costs of using contraception (perceived barriers) (King et 
al., 2016). Evaluation of the costs of contraception includes the convenience of obtaining and 
using a method and the safety and side effects associated with the method. 
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Personal convenience and physical satisfaction remain key considerations in the cost 
analysis of contraceptive acceptability for many men. Studies have found that a daily oral pill is 
commonly viewed by men as the most desirable method, followed by a monthly or 
several-monthly injection (WHO, 1980; Weston et al., 2002; Heinemann et al., 2005; Martin et 
al., 2000). Concerns about pain or the hassle of a regular regimen would thus be weighed against 
the downsides of condom use, of which the most commonly reported concerns include 
embarrassment and reduced sexual pleasure (Grady et al., 1993; Pleck et al., 1991; Institute of 
Medicine, 1995). One hormonal contraceptive trial participant explained his involvement as 
motivated by the lack of satisfactory alternatives: “[my partner] had an infection and then I sort 
of looked at the alternatives or rather the lack of alternatives, and thought, ‘No, thank you,’ 
because we were not using condoms, which you don’t more often than you do, let’s be honest” 
(Ringheim, 1996, p. 81). Such determinations are thus relative, conditional, and utility-driven, 
and men and women appear to employ different criteria for method acceptability in practice.  
This remains particularly true with respect to weighing perceived costs against the 
perceived susceptibility and severity of pregnancy and its consequences. One edition of 
Population Reports​, a Johns Hopkins University journal, recognized this inherent discrepancy, 
portraying a pregnant man with the text: “Would you be more careful if it was you that got 
pregnant?” (Gallen, Liskin, & Kok, 1986, p. 889). With the revolutionary control that modern 
contraceptives have given women over their bodies, women continue to make trade-offs for the 
sake of having the safe and independent sex life that men have generally been afforded. 
Moreover, aside from the clear social, economic, and health benefits of being able to choose 
whether and when to become pregnant, female hormonal contraceptives can provide 
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noncontraceptive benefits such as the improvement of menstrual patterns, alleviation of 
menstrual pain, and reduction of acne (American Society for Reproductive Medicine, 2011). 
Women are therefore often willing to tolerate the drawbacks of contraceptives.  
By contrast,  Brooks (1998) found in a survey that while a male pill was overwhelmingly 
ranked as the preferred choice for a new contraceptive method, over 70% of those questioned 
indicated that they would not tolerate any possible side effects. In the survey by Ipsos, which 
similarly demonstrated overwhelming male and female interest in a male contraceptive, women 
believed that men would be willing to tolerate minor side effects such as injection site pain, 
weight gain, and mood changes more than men reported themselves willing to be (2017). One 
male participant in a clinical trial stated: “Most of my male friends thought it was a good idea but 
when I actually told them what it involved—an injection once a week—they said: ‘Well, she can 
stay on the bloody pill!’” (Ringheim, 1996, p. 87). These findings and personal accounts suggest 
that men are unlikely to tolerate the same drawbacks that women routinely do, for they lack that 
urgent need for better methods that once contributed to the rapid and widespread uptake of the 
female pill. One female editorialist highlighted this obstacle: “[a man] can already avoid 
unwanted pregnancies if his partner is on birth control; with his own he’d get the same 
advantages, except now he might have mood swings” (Beck, 2016). The historical record of 
contraceptive development has made clear the extent to which differences in acceptability are 
grounded in the different stakes of unintended pregnancy, which I will discuss later in greater 
detail. 
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Fertility, Virility, and Manhood 
One of the central determinants of male contraceptive acceptability from the perspective 
of both users and researchers is a method’s impact on male sexuality and sexual function, which 
factor heavily in historical and cultural expectations about what truly defines a man. Reluctance 
toward male contraception may in part be rooted in the corporeal association of manhood with 
virility and fertility. This association was recognized as an important consideration during the 
development of early hormonal contraceptives. One psychoanalyst ​warned in 1966 that a man’s 
ability to impregnate unimpeded by technology was critical to his identity, stating that “for a lot 
of men, masculinity is a purely physical matter…[seen] in terms of what they can do to women” 
(Tone, 2001, p. 252)​. ​In 1968, a Merck researcher remarked that “the most difficult obstacle, 
perhaps, to a ‘male’ approach is the ‘emotional-psychological’ factor. The delicate male psyche 
equates virility with fertility, and it is believed that extensive education would be required to get 
men used to the idea of a ‘male’ contraceptive” (Tone, 2001, p. 252). From the initial stages of 
modern contraceptive design, assumptions about the innate value of male sexuality disqualified 
them from being able to “handle” hormonal contraception. 
Conventional wisdom treats male sexuality as a “totemic illusion, such that male 
sexuality became naturalized as both a fixed entity and as something entirely distinct from 
female sexuality” (Gutmann, 2007, p. 131). Balswick (1972) similarly theorizes that some men 
may feel that tampering with their own reproductive system violates their sexuality more so than 
it does for women. He suggests that sterility in a man may be viewed subconsciously as a sign of 
feeble masculinity or virility, while in a female it is seen solely as an inability to conceive, and 
quite unrelated to her femininity. In the United States, for example, female sterilization is 
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currently twice as prevalent as vasectomy, despite the fact that vasectomies are equally effective, 
less invasive, and carry a lower risk of complications (United Nations, 2015b; Watkins, 2012; 
Caron, 2019). In a survey of the attitudes of lower-class men toward taking a male contraceptive 
pill, Balswick (1972) found that the second most common reason given for objecting to a male 
pill, after the fear of harmful effects, was that “it is against nature” (p. 197). This response 
suggests that a man’s reluctance to hormonal manipulation may extend beyond reasoned 
objections and rely more upon an instinctual aversion to inference in his bodily integrity. One 
male contraceptive technology in the early stages of development is the so-called “clean sheets 
pill,” a drug that would produce a semen-free orgasm, effectively eliminating the physicality of 
ejaculation. If the exhibition of fertility remains a crucial aspect of the masculine image, the 
cultural feasibility of methods such as this will have to be investigated. Considering  such 
meanings, it is possible that tampering with a man’s reproductive potential, despite its 
reversibility, may be viewed by some as emasculating. 
It should be recognized that meanings of sexuality and masculine identity are not only 
performative but culturally specific, and their significance may differ between populations. For 
instance, Carl Djerassi, ​a chemist best known for his work in steroid chemistry, a key 
contribution to the development of oral contraceptive pills,​ suggested that in Latin America “the 
concept of ‘machismo’ and the preoccupation with potency would make it very unlikely that 
such a male Pill would find significant acceptance unless it could be claimed...that it also 
improved sexual performance” (1994, p. 69). Szasz (1998) reviewed a number of studies to 
explore this meaning among Mexican men, arguing that sexual prowess is viewed as a means to 
prove masculinity and the fathering of children has long been the emblem of manhood, 
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especially if a man lacks economic resources. Signs of sexuality such as “erections and 
penetration are considered the most valuable forms of male sexual expression; the male genitals 
represent courage, pride, arrogance, strength and well-being” (p. 97).  Culturally, there exists a 
contempt for weakness and passivity, which is considered effeminate. Szasz posits that these 
meanings may contribute to low use of contraception. Balswick (1972) makes a similar point 
with regards to socioeconomic status, suggesting that fears of emasculation may be heightened in 
populations that have historically held a lower status, and that an individual might feel he was 
being “asked to deny a masculinity which he feels he has never had” (p. 198). Theories such as 
these suggest that acceptability of male contraception will likely differ between populations. 
Martin et al. (2000) conducted a multi-center study to assess men's attitudes to proposed novel 
hormonal methods, in which 44–83% of men in Edinburgh, Cape Town, Shanghai and Hong 
Kong stated that they would use a male contraceptive pill. This percentage range reflects the fact 
that method preference and willingness varied greatly between countries, similarly indicating 
that a culturally-specific lens must be applied when forming new visions of masculinity.  
Researchers agree that for a potential male contraceptive method to be acceptable to men, 
it is essential to ensure that libido, an androgen-dependent phenomenon, is not impaired. Indeed, 
studies of acceptability of hormonal contraceptives have reported a consensus among potential 
users that noninterference with sexual functioning is an important factor, along with safety, 
efficacy, and reversibility (Davidson et al., 1985; Martin et al., 2000; Ipsos, 2017). Because 
hormonal contraception alters the secretion of male sex hormones responsible for such 
functioning, users’ concerns about sex drive and performance have been considered amply in 
design of contraceptive technology. The value placed on men’s sexual well-being has already 
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been made visible in the development of male condoms, which have been continually improved 
to maximize sensation and thus pleasure. The disproportionate attention paid to male sexuality in 
biomedicine was emphasized by the launch of Viagra in 1998 for erectile dysfunction, which, 
despite a sizeable list of potential side effects, was immediately and widely successful: 
“Apparently, a pill that enhances the potential for men to impregnate women is considerably 
more marketable than one that diminishes that possibility” (May, 2010, p. 116). The approval 
and success of Viagra in contrast to the absence of hormonal contraception indicates that in the 
field of reproductive medicine, priorities for men and women vastly differ. 
Although hormonal manipulation has the capacity to affect sexual function in both men 
and women, this concern has merited significantly greater consideration in formulations for men 
than in those for women. Few studies have explored current female methods’ effects on women’s 
libido or enjoyment of sex. Current available data suggest that the pill may alternatively increase 
or decrease libido, although most women are not presented with this information (May, 2010). 
The inattention to how women’s contraceptive methods affect female sexuality is striking when 
juxtaposed with the attention such an issue receives with regard to hormonal methods in 
development for men. This asymmetrical attention paid to sexuality may in part reflect the real 
and differing priorities of men and women in obtaining birth control. It has been observed that 
while men’s concerns typically revolve around how it might affect sexuality and intercourse, 
women’s concerns about hormonal contraception typically revolve around emotional and 
physiological side effects (RamaRao et al., 2008). Despite this, the hyper awareness of male 
sexuality in medical interventions in the male reproductive body, in contrast to the minimal 
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consideration given to the female body, is just one way in which prospective male hormonal 
contraceptives will face greater scrutiny than their female counterparts. 
 
Partner Dynamics and the Influence of Trust   
Contraceptive behaviors and decisions, however, can never be fully captured by 
characterizing the individual user alone. Studies have emphasized the importance of the attitudes 
and preferences of the female partner in contraceptive decision making. Real or anticipated 
endorsement by a female partner is a powerful predictor of male inclination to consider 
contraceptive use, and encouragement by female partners has been observed to positively 
influence men's willingness to volunteer for clinical trials (Martin et al., 2000; Ringheim, 1995). 
The degree of trust and the desire for personal reproductive control shape the ways in which 
contraceptive use is negotiated between partners. Because contraceptive failure has far greater 
personal consequences for women, method efficacy is generally of greater salience to them. 
Nevertheless, it has been observed that despite the greater risks associated with pregnancy and 
the greater personal investment, female compliance with daily oral contraceptive regimens, as 
well usage of other hormonal methods such as the hormonal vaginal ring, is “remarkably 
uneven,” which for many women reduces their contraceptive efficacy from 99% to 
approximately 91% (Planned Parenthood, n.d. (a)). This gap between theoretical and real 
protection in women’s typical birth control practices raises the question of whether compliance 
would be even worse among men, for whom the consequences are less direct (Potts, 1996).  
Any discussion of the acceptability and use of a male hormonal contraceptive therefore 
necessitates consideration of whether women would trust their partners to use a method with a 
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rigid regime reliably, particularly a method that cannot be verified in the moment. For this 
reason, “prospects for new methods for men probably hinge as much, if not more so, on how 
they are perceived by women” (Ringheim, 1996). To address this factor, Glasier et al. (2000) 
surveyed nearly 2,000 women attending family planning clinics in Scotland, China, and South 
Africa, and found that a majority of women felt that the responsibility for contraception falls too 
much on women. Glasier et al. found that despite differing cultures, beliefs, and personal 
contraceptive experience, more than two-thirds of the women thought that male hormonal 
contraception was a good idea, and only 2% of respondents reported that they would not trust 
their partner to use hormonal contraception. It was concluded that “on the whole, many women 
have rather cynical views of men in general which do not reflect their views of individual 
men—especially their partner” (Glasier et al., 2000). In another questionnaire, women 
acknowledged that “in a trusting relationship, either partner can be counted on to use 
contraception,” however “You’d never trust trust a man that you’d just met. You’d laugh, 
wouldn’t you? ‘Show me your certificate or show me some documentation that you’re using 
contraception’” (Ringheim, 1996, p. 84-5). This distinction between the high level of trust 
between individual partners and the lack of confidence in men as a broader population challenges 
the popular assumption that women are not willing to share the responsibility, and that men 
cannot be trusted. 
There does, however, appear to be some discrepancy in the confidence that men and 
women might feel in their partner in a situation of shared contraceptive responsibility. Eberhardt, 
van Wersch, & Meikle (2009) similarly assessed men's and women's attitudes toward the male 
contraceptive pill and their trust in the effective use of the male pill using a self-administered 
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questionnaire in England. They concluded that while both genders had favorable attitudes 
towards the male pill, women had a more positive attitude than men, but less trust that it would 
be used effectively by men. Interestingly, Ringheim (1996) interviewed some men who raised 
the issue of trust from an alternative perspective, suggesting that because a man could 
unwillingly and unknowingly impregnate a woman who took sole responsibility for reliable and 
effective contraceptive use, he might in fact prefer to rely on himself. Such an opportunity might 
be attractive to single or non-monogamous men seeking greater personal contraceptive control. 
Overall, however, studies have found that men in stable sexual relationships were generally more 
positive about the male pill than those in casual sexual relationships (Eberhardt, van Wersch, & 
Meikle 2009; Ipsos, 2017). The survey conducted by Ipsos indicated that many men and women 
believe that male contraceptives could enhance intimacy by reducing stress related to pregnancy 
risk (2017). The importance of trust in contraceptive use suggests that the target demographic for 
non-barrier male contraception would be men in stable, monogamous partnerships, for it remains 
questionable as to what extent women would be willing to rely on men’s use of a systemic, 
undetectable method except in the context of a long-term committed relationship. The focus on 
this particular consumer base is further supported by the inability of hormonal contraception or 
other non-barrier methods to protect against sexually transmitted infections (Ringheim, 1993). 
The results of these studies overall confirm that gender, relationship type, and trust in the 
effective use of contraception influence attitudes towards a long-acting male contraceptive. 
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Beyond Social Transformation  
As demonstrated in studies conducted over multiple decades around the world, there is 
mounting evidence that men are willing to play a more active role in in contraceptive efforts than 
that assigned to them in traditional family planning schemas, whether motivated by a belief in 
gender equality and fertility control as a shared responsibility, a sense of obligation to lift the 
burden from their partners, or a desire for control over their own reproductive body. While 
general reluctance appears to be declining, it should be acknowledged that not all men can be 
expected to support such a shift, and those who express theoretical interest may not be willing to 
venture far beyond their comfort zone. However, Ringheim (1996) points out that, as with all 
instances of social change, the “early adopters” of a technological innovation are a select group, 
and may not represent the population as a whole, “yet their motivations, interest and enthusiasm 
may portend a broader social revolution” (p. 80). In order to foster the cultural conditions in 
which a new male contraceptive is viewed as a potentially viable and worthwhile objective by 
those who can create such a product, we must ensure that consumer interest is vocalized.  
Moreover, in order to foster the cultural conditions in which such a technology would 
succeed, we must encourage the gradual shifts that have been taking place in recent decades. 
Solomon et al. (2007) suggest that efforts to bring men into the contraceptive world on a broad 
scale through the restructuring of gender norms may benefit from the language of “male 
transformation” rather than “male involvement,” as this terminology challenges men to 
drastically reorient their understandings of their masculinity (p. 3). This may be slowly working. 
In the wake of the feminist challenge to traditional gender norms, “a new concept of manhood 
that includes qualities of caring and taking responsibility has eroded earlier attitudes that equated 
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masculinity with sexual conquest” (May, 2010, p. 112). ​Moreover, a greater emphasis on the 
importance of male participation in fertility control has the potential to erode reluctance 
surrounding the personal inconveniences of contraceptive use, for a “strong motivation to limit 
fertility increases the willingness of individuals to use a method; the weakly motivated are more 
difficult to satisfy” (Ringheim, 1993, p. 93). 
However, while the transformation of sociocultural norms will prove essential to the 
integration of a new male contraceptive, consumer interest must be matched by a viable product. 
Currently, men have limited options for greater participation, and have relatively little 
knowledge of what could potentially be made available. We must therefore assess the 
possibilities for turning this demand into a reality by examining the scientific feasibility of this 
task. 
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Chapter 3: Scientific Feasibility and The State of Research  
Inherent Biological Challenges? 
Some researchers and other key figures have invoked biological rather than psychological 
explanations for ​the asymmetry in available contraceptive methods, and the preponderance of 
female methods has been attributed to “nature,” rather than to a “male conspiracy” (Tone, 2001, 
p. 253). It has been argued that due to fundamental differences between male and female bodies, 
the male reproductive system by nature is more resistant to intervention than that of women. 
While medical and philosophical ideas that the female body is closer to nature have been 
propagated in various forms for centuries, scientific understandings of the male body have 
identified certain physiological challenges. Several general approaches to male contraception 
have so far guided research in the field: Research has focused on alternatively inhibiting sperm 
production, interfering with sperm maturation, or inactivating or blocking sperm once it is 
produced. Substantially more work has been done on the first approach, primarily through 
hormonal interventions analogous to those employed in female hormonal contraceptives. 
However, several key differences between the male and female reproductive body present unique 
challenges in translating the techniques utilized in female reproductive technology to a viable 
male version. 
To begin with, the constancy as well as the sheer volume of sperm production appear to 
make it a daunting target for intervention in comparison to the cyclical and limited nature of the 
female reproductive process. ​A ​woman is born with a finite number of immature eggs, of which 
the vast majority will decline in quality over her lifetime. By the onset of puberty, only about 
300,000 remain, of which only approximately 400 will ever mature and be released during a 
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woman’s reproductive lifetime (“Female Reproductive System,” 2012). ​Female h​ormonal 
contraception works primarily by inhibiting ovulation, which occurs once a month and entails the 
release of a single egg. Oral contraceptives contain synthetic sex hormones, either a combination 
of estrogen and progestin or progestin alone. The administration of synthetic hormones works to 
stabilize ​hormone levels within the female body, preventing the spike in estrogen that usually 
occurs midway through the menstrual cycle and sets off a chain of signals that lead to ovulation. 
Without this spike, ovulation is prevented and no egg is released to be fertilized. The hormones 
additionally thicken the cervical mucus, incapacitating sperm within the female body. The birth 
control patch, vaginal ring, implant, shot, and hormonal intrauterine device all function in similar 
ways, delivering low doses of hormones over time. These methods may be used for years at a 
time, with fertility in women generally ceasing around the age of 45 (CDC, 2017).  
By contrast, contraception in men requires intervention in the production of large 
numbers of sperm cells that are produced daily throughout a man’s lifespan, with​ no period 
during which sperm production stops. ​The average male produces 1,000 sperm per second, and 
will produce more than 500 billion sperm cells over a lifetime (White et al., 2013). On average, 
men release about 180 million sperm every time they ejaculate, and it takes a single sperm to 
fertilize an egg (SciShow, 2018). Some reproductive scientists argue that it is much easier to 
control a single monthly event such as ovulation than to prevent the constant mass production of 
sperm. Interestingly, the same biological insights have been used to justify opposing viewpoints. 
Others have argued that the very qualities that seem to present challenges may in fact make the 
male reproductive system easier to manipulate:  
 
 
 
         48  
“There is no evidence that it is more difficult to prevent ‘billions’ of sperm from 
being produced, or acting, than one egg. The difference is not the numbers produced, but 
the discontinuity of egg production in the female and the continuity in the male. In many 
ways, it is easier to target a continuous process” (Schwartz, n.d.).  
However, an argument on the basis of numbers does not fully hold up, for the thresholds of 
contraceptive efficacy differ greatly in male and female bodies. In male bodies, with densities 
above 15 million sperm per milliliter of ejaculate considered to be normal, the current consensus 
is that lowering the sperm count below one million per milliliter, still seemingly a large amount, 
is a significant enough inhibition spermatogenesis to provide reliable contraceptive efficacy, 
reducing fertility by 99% (Mayo Clinic, 2018; Kean, 2012).  
In addition to key differences in quantity of production, some have highlighted variations 
in the stages of each process, explaining that “the number of ‘vulnerable links’ in the female 
chain of reproductive events was greater, rendering the woman a more suitable subject of 
contraceptive research” (Tone, 2001, p. 253). In this view, the male reproductive system is less 
complex yet more difficult to suspend:  
“Is the failure thus far to find a new male method comparable to the pill indicative of 
male disinterest in women’s well-being? I don’t think so. The simple fact is that the 
number of targets...is far more limited in males than females….Even the forces of 
women’s liberation cannot change the fact that the reproductive analogies between male 
and female end with sperm transport and egg transport, and that all subsequent events 
potentially subject to controlled interference occur only in the female.” (Segal, 1972, p. 
21-22)  
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If male and female reproductive processes function so differently, it must be asked why we 
continue to pursue a male pill to mimic the activity of the existing female pill. Some of these 
views have become antiquated as endocrinology advances, ​and biologists have pointed to 
similarities in the hormonal regulation of the reproductive system in males and females, 
identifying similar potential targets of intervention. In addition, these contradictory views on the 
feasibility of contraceptive mechanisms illustrate the interpretive flexibility of biological facts, as 
a result of which the same biological phenomena may be interpreted as either facilitating or 
constraining the possibilities for intervention in the male reproductive system. 
If the constant production of sperm can successfully be inhibited, the delayed effect of 
such inhibition presents a remaining issue. Spermatogenesis is an approximately 70-day process, 
with the result that male hormonal contraceptive would take several months to become effective, 
with a similarly long period needed to regain sperm function after ceasing the method. It has 
been recognized that such a delay would likely be deemed inconvenient and disfavored in 
comparison to the relative expediency of female contraception (Taylor, Aldad, & McVeigh, 
2012). ​It is, by contrast, fairly easy to use a low dose of hormones to fool a woman’s ovaries into 
believing she is pregnant: the prevention of ovulation can be achieved within a week of hormone 
treatment. Yet while these differences could represent ​obstacles to widespread acceptability and 
utility, they do not appear to create insurmountable challenges. 
 
The Hormonal Approach 
Despite the recognized physiological challenges, the sequence of events leading up to 
fertilization affords many potential sites for contraceptive action, which have been explored via a 
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variety of approaches in preclinical and clinical studies over the course of decades. As previously 
stated, suppression of sperm production through hormonal intervention has received 
disproportionate attention. Decades of research have culminated in a more advanced 
understanding of hormonal manipulation of the male body: that male fertility may be temporarily 
interrupted by interference with hormonal control of the testes. Sperm are produced in the testes, 
where testosterone is also produced. Testosterone levels in the testes are 25 to 125 times higher 
than in the blood; these high concentrations are required for sperm production (Amory, 2017). 
Suppression of sperm production using both male and female sex hormones has been 
demonstrated since the middle of the 20th century (Heller et al., 1950). Operating on the same 
principle as female oral contraceptives, these early studies aimed to artificially raise sex hormone 
levels in order to trick the body into shutting down endogenous production of the hormones 
required to produce sperm. When exogenous testosterone is administered in the male body, 
artificially raising its levels, the brain and pituitary gland sense that systemic levels are high 
enough and halt production in the testes, causing concentrations in the testes to drop and 
consequently inhibiting spermatogenesis (Moudgal & Suresh, 1995). 
Clinical trials of hormonal contraceptives for men in various dosages and combinations 
began in the 1970s, as mentioned previously. The International Committee for Contraception 
Research (ICCR) began testing various types of progestins, synthetic hormones that exert action 
similar to the female sex hormone progesterone (Schearer, 1978). Because these hormones were 
already in widespread use for more than a decade in oral contraceptives for women, a fair 
amount was already known about their pharmacological properties. Despite their moderate 
efficacy in suppressing sperm count, many dosage regimens were reported to cause side effects 
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such as loss of libido, liver toxicity, moderate weight gain, and “symptoms of femininity” such 
as gynecomastia, or the development of breasts (Schearer, 1978). Schearer hypothesized in one 
review of existing research that some cases of decreased libido constituted psychological 
reactions caused by apprehensiveness about the treatment rather than pharmacological side 
effects produced by the hormones tested (1978). Studies of androgens, or male sex hormones, 
which are responsible for various “masculine” characteristics, resulted in similar efficacy rates 
and similarly unacceptable side effects. One 1981 study found that in some men, a daily 
hormonal injection caused a loss of sex drive and “​momentary increases in body temperature, or 
so-called hot flashes, such as those experienced by women after menopause” (“Male 
Contraceptive is Tested,” 1981). For reasons discussed previously, these downsides were 
repeatedly found threatening enough either to personal health or to personal confidence to 
disqualify such compounds or combinations.​ Most early study regimens presented additional 
practical challenges: time to efficacy and return to fertility were both significantly delayed: 
ranging from six to 20 weeks and 12-18 months, respectively (Schearer, 1978). From a technical 
standpoint, the hormonal research conducted in the latter part of the 20th century proved that this 
approach had promise, yet required further refinement in order to eliminate adverse effects and 
inconsistencies in efficacy.  
Despite decades of experimentation and alteration, investigators maintain that a product 
that satisfies principles of safety, efficacy, reversibility, and acceptability is yet to be met with 
success. A combination of both testosterone and progestin is now believed to be the most 
promising formulation. When administered together, the two hormones appear to increase the 
rate and extent of suppression, while the exogenous testosterone serves the additional purpose of 
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preserving libido and male sex characteristics. However, common side effects of hormonal trials 
continued to include acne, mood changes, weight gain, and injection-site pain (Kopf, 2016; 
Christensen, 2000). Moreover, researchers have encountered fairly high nonresponder rates to 
hormonal treatments, as well as unexplained differences between races: one study found that 
Asian men maintained a suppressed sperm count with greater frequency than Caucasians 
(Goodman, 2008).  
Researchers have additionally faced technical difficulties establishing a safe and 
convenient delivery method. Oral testosterone clears the body too quickly for once-daily dosing, 
and would instead require two doses a day to maintain high enough levels (Kean, 2012). A 
further concern is that available oral forms of testosterone may cause liver inflammation 
(Endocrine Society, 2018). Clinical attempts have therefore explored alternative methods of 
delivery, including weekly or monthly injections, twice-a-year synthetic implants in the arm, and 
daily topical gels (Osborn et al., 2003; Seppa, 2012; “NIH to evaluate effectiveness,” 2018). 
According to preference ratings gathered in surveys, periodic injections are generally deemed 
less convenient than a daily pill that can be taken at home and thus may face greater scrutiny 
with regard to common use (Kean, 2012). In this regard, a topical gel may provide a viable 
alternative: in early tests of one combination gel, 89% of men achieved sperm counts below one 
million—a low level of sperm production indicating comparable contraceptive efficacy to that of 
the female contraceptive pill (Ilani et al., 2012). Importantly, most study participants reported 
that they were satisfied with the regimen and would use it if it became commercially available, 
and the product has progressed to larger clinical trials (Roth et al., 2014).  
 
 
 
         53  
More recently, a new hormonal compound has shown promise in bypassing the delivery 
issues associated with oral testosterone. The work on dimethandrolone undecanoate, or DMAU, 
was first presented in 2018 by the National Institute of Child Health and Human Development 
(NICHD). The compound, which is receiving considerable attention, has a different structure 
than testosterone that slows clearance and allows it to remain in the body for longer, which keeps 
levels steady enough to be taken once a day. The compound binds to the same hormone receptors 
as do testosterone and progestin throughout the body. It can be administered via injection or pill, 
and similarly tricks the body into producing less testosterone, thus reducing concentrations in the 
testes and inhibiting sperm production. The compound has worked well in animals, and is now in 
the preliminary stage of clinical trials. Researchers had 83 men between the ages of 18 and 50 
take DMAU in pill form daily for 28 days. At the highest dose tested, subjects showed “marked 
suppression” of testosterone levels. Sperm count itself was not measured, as this study was 
primarily conducted to assess the pill’s safety. Despite their low levels of circulating 
testosterone, few subjects reported symptoms consistent with testosterone deficiency, including 
changes in sex drive and sexual function. Furthermore, all subjects passed the safety tests, 
including markers of liver and kidney function, although participants did experience mild weight 
gain and slight decreases in HDL (“good”) cholesterol. The team expects to begin another study 
soon that will follow men taking the pill for a longer period of time, in which semen samples will 
be collected to measure levels of sperm production (Endocrine Society, 2018). Another hormonal 
pill, 11-Beta-MNTDC, considered a “sister compound” to DMAU, very recently passed Phase I 
tests of safety and tolerability when healthy men used it daily for a month, and similarly 
produced hormone responses consistent with effective contraception without causing severe 
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adverse effects. These results suggest that these compounds will decrease sperm production 
while preserving libido (Endocrine Society, 2019). Thus, current work, while still in its early 
stages, represents a promising step forward in the development of a commercially viable 
hormonal method. 
 
Non-Hormonal Approaches 
In response to various past challenges posed by hormonal methods, the attention of the 
research community has also shifted to expand its net to include promising non-hormonal 
methods. These include several drugs that disrupt the process of sperm maturation, rendering 
them incapable of fertilization. While several new compounds have shown efficacy in animal 
testing, none have yet been tested in humans. These include Adjudin, a compound that breaks the 
adhesion of immature sperm to the cells that “nurse” them and would likely be administered by 
patch or implant (Mok et al., 2011). Before it can be studied in humans, researchers must find an 
effective and affordable way to inhibit an autoimmune response to the compound (Amory & 
Bremner, 2016). H2-Gamendazole, which would be taken orally, is a compound that inhibits 
growth of the head and tail of the spermatozoon. These immature sperm fragments would then be 
reabsorbed into the body. Researchers are currently investigating potential tissue toxicity, as well 
as the physiological impact on the female partner if the compound remains in the semen (Tash et 
al., 2008).  
Andrologist John Amory at the University of Washington School of Medicine is currently 
exploring another novel non-hormonal approach: inhibition of the conversion of retinol (vitamin 
A) to retinoic acid, a process necessary for spermatogenesis. The vitamin A that we ingest is 
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converted by a family of enzymes into retinoic acid within the body, and one of these enzymes is 
found exclusively in the testes. The blockade of this enzyme with an antagonist would deprive 
the testes of retinoic acid, thus preventing sperm production without affecting the function of 
vitamin A elsewhere in the body. This approach has been tested in animals, and Amory reports 
that he hopes to test it in humans soon (Hogarth, Amory, & Griswold, 2011).  
Thermal techniques represent another approach that has proven worthy of exploration 
over time. Fahim et al. (1975) initially researched the potential for heat as a means of male 
contraception, and showed that a short treatment with ultrasound caused infertility in rats. Fahim 
hoped to interest electronic companies in creating an ultrasonic device that could be bought and 
used at home. He also explored the design of a contraption similar to a heated undergarment that 
could be worn temporarily (May, 2010). Tsuruta et al. (2012) conducted a recent study to 
continue this work, aiming to determine whether a commercially available therapeutic ultrasound 
device could be used as a male contraceptive. The non-surgical and non-pharmacological nature 
of ultrasound could make it and similar heat-based methods promising candidates for a male 
contraceptive. The team of researchers concluded that further studies must be conducted to 
confirm its efficacy, verify its reversibility, and track any potential long-term detrimental effects.  
Phenoxybenzamine, known as the “clean sheets pill,” is a fast-acting drug meant to 
produce a semen-free orgasm and represents another exciting non-hormonal candidate. The drug, 
which is currently used to treat high blood pressure, acts by relaxing muscles in the vas deferens 
to prevent transport of sperm and ejaculation without affecting the male orgasm. This drug 
moreover provides a unique advantage in its potential to prevent STI/HIV transmission in 
addition to pregnancy. Although its ability to cause aspermia has been known for decades, 
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exploration of the drug as a contraceptive agent remains in its early stages for reasons I will 
address later (Homonnai, Shilon, & Paz, 1984; Parsemus Foundation, n.d. (b)).  
One of the most promising current projects is a long-acting, non-hormonal method called 
Vasalgel that functions like a reversible, non-surgical vasectomy.​ In vasectomies, the vas 
deferens, ​the tube that transports sperm from the testicle, is the site for contraceptive 
intervention: the tube is cut and tied, preventing the flow of sperm. ​Vasalgel is a polymer 
material that is injected with a syringe into the vas deferens​, where it ​remains in a soft gel-like 
state that filters out sperm while allowing the passage of other seminal fluids (Revolution 
Contraceptives, n.d.). Sperm are unable to reach and fertilize an egg, and neither sperm 
production nor male hormone levels are affected. ​The procedure takes approximately 15 minutes 
with local anesthetic, and once injected, the gel could be effective for up to 10 years. The process 
can be reversed at any time with a second injection that breaks down the polymer gel and flushes 
it out, allowing sperm to pass through the vas deferens normally. ​Vasalgel has been in 
development since 2010 by the Parsemus Foundation, a U.S.-based nonprofit organization with a 
stated mission to “[advance] innovative and neglected medical research” (Parsemus Foundation, 
n.d.). 
Vasalgel was inspired by a technique called RISUG, or ​reversible inhibition of sperm 
under guidance, which was originally developed in India in the 1970s by Sujoy Guha, a 
biomedical engineer at the Indian Institute of Technology. RISUG ​works by causing an electrical 
charge disturbance. The gel coats the walls of the vas deferens, and the positive charge of the gel 
results in rupturing of the negatively charged sperm membranes, damaging the sperm and 
rendering them nonviable (Sen, 2002). The technique ​uses a similar formulation to Vasalgel, but 
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lacks the chemical stability required by FDA standards. ​RISUG has been developed and tested 
over multiple decades: Phase I clinical trials were conducted in the early 1990s, and advanced 
Phase III clinical trials are presently underway in India, where​ over 500 men have received the 
injection as of 2017 ​(Sen, 2002; Altstedter, 2017)​. The procedure has been shown to be 98% 
e​ffective at preventing pregnancy with no major side effects, according to R. S. Sharma, head of 
reproductive biology and maternal health at the Indian Council of Medical Research (Altstedter, 
2017). Unlike the pill and condoms, which have a real-life efficacy rate lower than that 
associated with the “perfect use” scenarios advertised, this contraceptive injection, like an IUD, 
leaves virtually no room for human error. 
Although human trials of RISUG in India are currently restricted to locals, Guha licensed 
the technology to the Parsemus Foundation in 2010 to help establish a market for the technology 
outside of India. The foundation chose to pursue its own variant, which it feels has a better 
chance of making it to market in the U.S. While Vasalgel has yet to be tested in human trials, 
preclinical animal studies have proven successful, with tests of Vasalgel in a rabbit model 
resulting in rapid and durable efficacy of the contraceptive. The study demonstrated that rabbits 
had no sperm in their semen as early as 29 days post-injection and the contraceptive effect was 
sustained throughout the 12-month study (Waller et al., 2016). Preclinical studies of reversibility 
were similarly promising, showing rapid restoration of sperm flow in all rabbits (Waller et al., 
2017). Further, a recently completed study in 16 adult male monkeys showed that Vasalgel was 
successful in preventing pregnancies after the primates fraternized with females for 1-2 breeding 
seasons (​Colagross-Schouten, 2017)​. However, reversibility of the contraceptive effect has not 
yet been demonstrated in these primates, and research is ongoing to clarify any issues and 
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optimize the procedure. While these results warrant continued development of the product, initial 
human trials will solely enroll men interested in a permanent contraceptive effect until 
reversibility of the contraceptive is proven in humans (Berry & Lissner, 2017).  
 
Beyond the Laboratory 
The chemical compounds and procedures highlighted in this chapter represent a handful 
of the dozens of male contraceptive methods under investigation, and demonstrate that current 
and ongoing projects show much promise. With such an abundance of prospects for further 
research, we must ask why research has progressed so slowly since such efforts were set in 
motion in the 1970s. In some ways, it seems that the history of the second half of the 20th 
century became one of an ever-widening gap between the insights of reproductive physiologists 
and their real-world application to fertility control. To be sure, as time passes and scientific 
insights and technological capabilities advance, possibilities in research gradually expand. Many 
promising compounds remain novel, and may require years to overcome key technical issues 
prior to their use by humans. However, other candidates appear ready for testing in humans, yet 
remain stalled in the laboratory. Still other candidates have been tested in humans, yet have not 
progressed to the stage of approval by the U.S. Food and Drug Administration (FDA). The state 
of male contraceptive research illustrates that the scientific community does not lack promising 
leads; instead, there remains a stubborn gap between laboratory discoveries and their conversion 
into a practical and acceptable products.  
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Chapter 4: From Laboratory to Market 
The Contraceptive Development Process 
The failure of any of the aforementioned experimental drugs and technologies to be 
translated into commercially viable products following decades of promising research, and the 
glacial pace at which such processes are now occurring for newer options, can be attributed 
primarily to regulatory and financial obstacles that have proven fundamentally intertwined. 
Heightened scrutiny of new pharmaceuticals born out of past mishaps has made it increasingly 
costly and time-consuming to bring new contraceptive methods to market (May, 2010). With the 
cost of new drug development hovering in the hundreds of millions of dollars, there are few 
options for adequate funding except from the pharmaceutical industry (Hartmann, 1995). 
However, innovation in the field of male contraceptive technology has been absent from the 
research and development (R&D) agenda of the industry for a long time.  
The willingness of pharmaceutical companies to invest in new product development is 
determined by the perceived presence of a market, potential profits, and risk of litigation. With 
uncertain forecasts of market demand and the risk of commercial failure weighed against the 
soaring costs of R&D and clinical trials, extraordinary safety and efficacy regulatory hurdles, 
and liability concerns, the pharmaceutical industry has all but abandoned the field of male 
contraceptive research over the past decade or so, leaving government agencies, nonprofit 
organizations, and start-up companies to pursue this objective and to procure funding with more 
difficulty. As a result, much past or current male contraceptive research has fallen victim to the 
drug development “valley of death,” a nickname for the gulf between laboratory success and the 
exponentially more costly human trials. Furthermore, the drugs that have made it to the clinical 
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trial stage without industry involvement have faced additional challenges as heightened scrutiny 
of adverse effects and ingrained double standards in gendered contraceptive development 
obstruct the testing and approval process. 
The drug development process in the United States is stringently regulated by the FDA. 
This process is even more rigorous when it comes to new contraceptive drugs and devices, which 
pleases some and frustrates others: “t​he balance between allowing ample opportunity to develop 
useful new products and protecting the safety of consumers is at the heart of the debate about the 
FDA's safety and efficacy requirements for new drugs generally and for contraceptives in 
particular” (NRCIM, 1990). Some believe that these requirements have driven up the cost of 
drug research and development and delayed drug innovation, and regard the FDA as a significant 
barrier to better contraceptive methods and therefore to fewer unwanted pregnancies and 
abortions. Others view the requirements as necessary to protect the public from unsafe or 
ineffective drugs. With the increasing commercialization of medicine and other therapeutic 
products, the FDA “must protect the consumer from harm and fraud, it must maintain and 
enforce appropriate analytical standards, and it must generally assume the function of policeman 
or watchdog” (Djerassi, 1994, p. 48). Still others view FDA standards as not rigorous enough 
and too easily influenced by pressures from private industry (NRCIM, 1990). 
For those who undertake the task of new drug development, the process is long, arduous, 
and resource-intensive. Pharmaceutical companies, government agencies, academic institutions, 
or nonprofit research groups must first conduct preliminary research, which includes ​finding 
promising drug candidates and studying their properties. ​Potential agents are tested in several 
rounds of preclinical animal studies to demonstrate proof of concept and safety. Since the 
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introduction of the first oral contraceptives in the 1960s, the FDA's requirements for 
toxicological testing of proposed contraceptive drugs have become more demanding than its 
requirements for the testing of other drugs. In the 1970s, the U.S. Food and Drug Administration 
(FDA) added a requirement that, prior to the initiation of human clinical trials, two-year toxicity 
studies in rats, dogs, and monkeys be completed (NRCIM, 1990). Clinical trials usually occur in 
three phases. In Phase I, the drug is given to a small number of usually healthy volunteers to 
establish safe dosage levels and to study its metabolism and side effects. Phase II, which 
involves up to several hundred patients, evaluates the efficacy of the drug. Phase III studies 
evaluate safety and efficacy in much larger numbers of patients, ranging from several hundred to 
several thousand, and may last for several years (Angell, 2004). Vasalgel, for example, after its 
demonstrated success in primates, is now required to pass these three rounds, meaning that it will 
If clinical trials are successful, results are submitted to the FDA for approval.  
Few drug candidates survive this scrutinizing process. According to estimates by Big 
Pharma, the umbrella term used to refer to the conglomerate of the world’s largest and most 
powerful pharmaceutical companies, only one in 5,000 candidate drugs make it to market: one in 
1,000 survive preclinical testing, and of those, only one in five make it to clinical testing (Angell, 
2005, p. 23). Indeed, many contraceptive drug formulations are discarded during the 
development process because of concerns about safety, efficacy, feasibility of delivery, or 
marketability. One study found that between 1963 and 1976, of 20 new chemical entities 
identified as potential contraceptive agents, 17 were placed into human trials, only three were 
submitted to the FDA for approval, and only two went on to be approved (NRCIM, 1990). 
Overall, the t​otal time from the beginning of preclinical testing of a candidate drug to its coming 
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to market ranges from approximately six to ten years; for new contraceptive drugs, that number 
may jump to 10 to 17 years (Angell, 2005; Hartmann, 1995). 
Contraceptive drugs and devices face particularly stringent clinical trial requirements 
from the FDA because, unlike most treatments, they are intended for potentially long-term use 
by millions of healthy people. Some argue that these requirements reflect a “demand for proof of 
safety that applies to all drugs but is, perhaps, uniquely burdensome to sponsors of 
contraceptives” (NRCIM, 1990). However, given the assumed pattern of use, rigorous 
requirements to ensure a high degree of safety are justified. Contraceptives may be used for the 
majority of a person’s reproductive years, which for women generally span several decades, and 
for men even longer: 
“The single greatest objection to the oral contraceptives now being used is the essentially 
continuous administration of a potent agent to fertile women for many years. Clearly 
even greater objection would be raised in the case of a male contraceptive pill if it had to 
be taken day after day by fertile males for many years, possibly 40 or more.” (Djerassi, 
1994, p. 46) 
The unique pattern of use associated with contraceptives thus sets them apart from other 
medicines in the risk-benefit analysis upon which FDA approval is contingent. If a drug 
demonstrably offers unique and dramatic benefits—if, for example, it saves lives or cures a 
severely disabling disease for which there are no ​comparable treatment options​—it is fairly easy 
to conclude that this risk of the unknown is worth taking ​(FDA, n.d.). By contrast, a multitude of 
effective, fairly well-understood female birth control methods exist, diminishing the urgency of 
the approval process of a new technology and making the risk of attempting the unknown less 
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compelling. ​In the face of such risk, it is often preferable to “​treat sick people with the hopes of 
curing them than healthy people with the hopes of not making them sick” (Beaton, 2017). 
All active drugs cause adverse effects in some users. If safety were understood as the 
total absence of adverse effects, then no drug could truly be called “safe.” Thus, the safety of a 
drug is conceived by regulators as a ratio of benefits to risks for the population of users as a 
whole. The value of the medical benefits provided by a drug is typically a matter of technical, 
quantifiable medical judgment, such as the lowering of blood pressure or the shrinking of 
tumors, as are the associated risks. ​However, the value of some benefits transcends a 
professional or quantifiable judgment, particularly in the case of contraceptive technology. While 
few disagree that the ability to determine the number and spacing of one's children can 
significantly influence a person’s health and economic well-being, s​cientists and physicians have 
difficulty assessing the value of avoiding an unwanted pregnancy or of the nonmedical aspects of 
a particular means of contraception because the criteria are less clear or are challenging to 
measure. ​The societal and personal costs of an undesired pregnancy are simply not equated by 
the public and by regulatory bodies to the immediately evident health consequences of a disease 
such as measles, cancer, or AIDS ​(​NRCIM, 1990). ​Despite this distinction, the oral contraceptive 
pill has been recognized by the WHO as an “essential medicine,” one that meets “the priority 
health care needs of the population” because of its “public health relevance, evidence on efficacy 
and safety, and comparative cost-effectiveness” (Watkins, 2012; WHO, 2017). Fertility control is 
thus of great value to women and men, and that value, even though unquantifiable, must be 
recognized in risk-benefit analyses. 
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With regard to users’ risk-benefit analyses,​ expectations are understood to differ based 
upon the seriousness of their need and the presence or absence of alternative treatment options. 
The choice to take on potential health risks is a much less straightforward calculation for a 
medication that improves quality of life than one that provides a direct and tangible remedy to 
illness. Demonstrat​ing that a male contraceptive is as safe and beneficial as existing female 
methods will prove even more difficult because its risks and costs cannot be similarly weighed 
against the risks and costs of pregnancy, making any risk at all difficult to justify to users, to the 
industry, and to the FDA. This challenge is further complicated by the generally indirect means 
by which men have been emotionally and economically linked to pregnancy and childbearing 
and rearing in society, with the result that improvement in quality of life is even less directly 
evident. 
 
Profit and Innovation in the Pharmaceutical Industry 
Although selective drug approval and rigorous safety standards are justified in the field of 
contraceptive development, the time, costs, and data required to gain approval of a new product 
have reduced the incentive to undertake innovative research because they detract from the 
profitability of new products, which remains the primary objective for pharmaceutical firms. 
Developers of new contraceptives protect their investment in research and development by 
securing patents, which grant inventors a number of years during which they have exclusive 
rights to manufacture and sell their products. Patentability thus influences corporate decisions to 
pursue new product development, and is especially valuable in the pharmaceutical industry. 
However, FDA requirements for data on a contraceptive product’s safety and efficacy and the 
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wait time for approval have contributed to a reduction in its effective patent life, making 
investment in R&D less attractive (NRCIM, 1990). Pitted against this loss, new contraceptives 
are not viewed as worthy ventures: one researcher lamented that “contraceptives are a retail 
business—it’s a matter of selling a lot, and profit is low” (Extance, 2016).  
Moreover, since the early 2000s, industry leaders, observers, and policy makers have 
been reporting an “innovation crisis” in pharmaceutical research. Claims have been made 
throughout the industry that the productivity of its research and development expenditures has 
been declining. In 2010, the investment bank Morgan Stanley recommended that, following “a 
decade of dismal R&D returns,” the major companies shift away from in-house research 
investment—essentially, that they stop attempting to discover new drugs and buy into 
discoveries by others (Light & Lexchin, 2012). However, according to Light and Lexchin 
(2012), data indicate that the widely touted innovation crisis in pharmaceuticals is a myth with 
most research and development at large pharmaceutical companies directed at developing minor 
variations on existing drugs rather than finding better drugs for unmet needs. This strategy is not 
specific to contraceptive drugs, but applies to the pharmaceutical market at large.  
In general, the​ few innovative drugs that do come to market nearly always come from 
publicly supported research, almost all of which is sponsored by the National Institutes of Health 
(NIH) and carried out at universities, small biotech companies, or the NIH itself (Angell, 2004). 
This work is often then patented and licensed to drug companies to market (Angell, 2012). Thus, 
many of Big Pharma’s drugs are now acquired from outside sources, and while ​“companies are 
delighted when research breakthroughs occur...they do not depend on them” (Light & Lexchin, 
2012). Moreover, physician and author Marcia ​Angell argues that R&D is a relatively small part 
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of the budgets of the big drug companies, and is “dwarfed by their vast expenditures for 
marketing and administration” (2012, p. xxiii). With the deep ties between industry and 
healthcare in the United States in particular, ​“pharmaceutical value has increasingly become a 
marketing proposition, not a scientific one” (Applbaum, 2009, p. 16). Angell argues that ​“drug 
company profits are so large that one would hope the companies would be willing to make less 
profitable but vital drugs as a social service….But that is not the way this industry works. It all 
comes down to dollars and cents” (2012, p. 92). ​With the increasing commercialization of 
medicine, the pharmaceutical business model is one that regularly prioritizes profits over public 
health objectives.  
This trend has been observed in contraceptive development. While birth control remains 
a basic health care need for persons of reproductive age, pharmaceutical companies have found 
little incentive for investing in the innovation of new methods. When the success of the first 
contraceptive pill became apparent, other pharmaceutical companies rushed to bring their own 
versions of an oral contraceptive to market. Eager to capitalize on the early success of oral 
hormonal contraception, researchers additionally sought other ways to deliver the hormones into 
women's bodies (Watkins, 2012). In the 1970s and ’80s, major manufacturers began to spend 
more money on modifications to formulations of existing steroidal contraceptives than on new 
methods (Tone, 2001). Meanwhile, nonprofit organizations undertook much of the research, 
development, and testing of alternative delivery systems for hormonal contraception (Watkins, 
2012). Chemist Carl Djerassi made a prediction in 1989 based on the trajectory of research at the 
time: 
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“All we can expect well into the beginning of the 21st century are minor 
modifications of existing methods: different delivery systems for steroids, possible 
improvements in sterilization techniques and barrier methods, more precise indications of 
the safe interval, and possibly a more realistic reconsideration of the IUD option. Such 
modest developments will extend contraceptive use patterns, but they will not affect our 
total dependence on conventional 19th and 20th century approaches to birth control.” 
This remains an accurate reflection of the current birth control landscape. Although there are two 
general types of oral contraceptives (combination and progestin-only) dozens of brand name 
variations of these pills exist today. With regards to efficacy, “no brand of pill has been shown to 
be more effective than any other” (“Which Birth Control Pill,” 2017). For pharmaceutical firms 
focused on profit, the safer bet continues to be to stick with current product lines, making 
occasional changes to the formulations without making any major innovations.  
A key reason for the pharmaceutical industry to avoid investment in male contraceptive 
research is the notion that such an avenue would provide limited opportunities for growth and for 
profits because the market was already saturated with existing products. In 2015, the global 
contraceptive market was worth $18.35 billion, according to a report by the global market 
research firm Transparency Market Research (Altstedter, 2017). Today more than 100 million 
women use the pill worldwide (Christin-Maitre, 2013). In fact, oral contraceptives are the most 
common form of reversible contraception in most developed economies of the world, including 
Western Europe, the U.S., Canada, and Australia.​ Because they have existed and been tinkered 
with for decades, they are fairly well understood. Pharmaceutical companies have moreover 
expanded their marketing of existing female contraceptive products beyond the function of 
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fertility control, advertising them for acne treatment or regulation of menstrual symptoms 
(Watkins, 2012). Female contraceptive technologies thus constitute a​ lucrative and 
well-established market​. 
With such a reliable base, new male contraceptives are not regarded as potential 
blockbusters. Diana Blithe, a program director at the NICHD, which funds male contraceptive 
research, suspects that some companies view contraceptives as a zero-sum game in which every 
dollar spent by consumers on male contraceptives would mean one less dollar spent on female 
contraceptives (Kean, 2012). In particular, cost-effective and long-acting treatments might 
undermine profits from daily methods such as the pill or expensive methods such as the IUD, 
which typically lasts for 3-5 years and for which costs may exceed $1,000 (Planned Parenthood, 
n.d. (b)). The Vasalgel injection, for example, does not have the ability to make large sums of 
money because it is a one-time procedure that lasts for up to a decade and uses materials that are 
relatively inexpensive to make and distribute (Parsemus Foundation, n.d. (a)). ​Yet the economic 
dimensions of ​male hormonal contraception have previously been studied by independent 
parties, suggesting a large potential market for profit. According to one 2012 estimate, ​assuming 
a market size of 10 million men in the U.S. and 50 million men worldwide, the market value of a 
new male contraceptive method could be worth $40 to $200 billion (Dorman & Bishai).  This 
estimate suggests the existence of multiple conflicting interpretations of the potential commercial 
viability of a male contraceptive product.  
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Industry Involvement in Contraceptive Research 
The unwillingness to invest in the costly pursuit of a new male contraceptive is thus 
primarily a result of monetary cost-benefit analyses. While one fear is that new male 
contraceptives would disturb the profits reaped from the multitude of female products that 
permeate the market, an alternative is that they would not attract enough users to be profitable, 
and would fail in the marketplace. Similar hesitancies surrounding consumer demand existed 
surrounding the development of the first female pill. During the initial years of contraceptive 
research and development in the 1950s, the pharmaceutical industry shied away from funding 
such activities. Companies feared negative publicity that might be generated by attempting to 
market a product that challenged the anti-contraceptive laws still in place in some states, and 
feared boycotts of their other products by Roman Catholic citizens, who opposed contraception 
and who made up 25% of the American population at the time (Watkins, 1998). Despite 
supplying the materials for clinical trials, G. D. Searle & Co., the company that went on to 
market the first contraceptive pill, Enovid, remained cautious about any association with a 
contraceptive drug. It was not until high initial sales of Enovid under the guise of treatment for 
menstrual disorders demonstrated its profitability that the company showed true interest in this 
endeavor. Searle’s public relations director later recalled: “we had underestimated the receptivity 
of the product. We got quite a surprise” (Tone, 2001, p. 225).  
Today, any perception of lack of consumer demand has more to do with gender norms 
and user preferences than with political or religious controversy. Many major pharmaceutical 
companies remain skeptical that men would embrace a male contraceptive with the 
accompanying inconvenience and potential side effects, or that male compliance with hormonal 
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regimens would be successful. Christensen (2000) remarked that “even in clinical studies, men 
sometimes find the complicated schedule of pills and patches or injections difficult to handle.” 
Despite weak support for this reasoning, such doubts provide the basis for the pharmaceutical 
industry’s general agreement that such an endeavor is simply not worth the investment of time 
and resources. 
The last major attempt by Big Pharma to create a male hormonal contraceptive occurred 
when Dutch company Organon and Germany company Schering AG teamed up in 2002, 
reporting that they were “optimistic to fill this gap” (Flynn, 2018). The two pharmaceutical 
giants joined forces to start a phase II multicenter clinical trial to test the reliability and 
acceptability of two hormones in combination which were known to have a suppressive effect on 
sperm production based on the results of earlier studies. The trial, however, was cancelled in 
2006 when the two companies dissolved the partnership, claiming that they would continue 
research efforts separately. The companies described the collaboration as constructive, with 
contraceptive efficacy demonstrated in approximately 90% of the men and post-treatment 
recovery of normal fertility. However the reported adverse events were deemed intolerable. 
Although the men experienced dramatic drops in sperm counts, they also experienced side 
effects such as acne, weight gain, and mood issues. It was moreover concluded that the 
administration route investigated in the trial, which combined an annual implant with 
three-monthly injections, was unlikely to result in a product that would be found acceptable for 
widespread use. ​The firms’ proclaimed individual efforts were dropped soon after: Schering’s 
research and development activities surrounding male fertility control was halted in 2007 when it 
was acquired by Bayer, one of the largest pharmaceutical companies in the world, and one of the 
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top sellers of female birth control (Sifferlin, 2018). Bayer concluded that men would consider the 
regimen, in the words of a spokesperson, “not as convenient as a woman taking a pill once a 
day” (Khazan, 2015). Organon’s program ended soon after, when it was acquired by 
Schering-Plough and subsequently Merck & Co. in 2009 (Flynn, 2018). A Merck spokesperson 
said only, “It is not a priority area” (Kean, 2012). 
An examination of why certain projects are prioritized while others are neglected must 
look beyond profit to consider the identity makeup of those involved in making these decisions. 
Significantly, there is a continued paucity of gender diversity within the pharmaceutical industry, 
particularly at the highest levels of leadership.​ ​Estimates indicate that only approximately 7-9% 
of chief ​executive roles in the industry are filled by women, despite the fact that women enter the 
field at a higher rate than men (Ramsey, 2017). Herjan Coelingh Bennink, who helped develop 
the female contraceptives Implanon and Cerazette as the head of Research and Development in 
Women’s Health for Organon International for more than a decade, emphasized that “the big 
companies are run by white, middle-aged males who have the same feeling—that they would 
never do it….If those companies were run by women, it would be totally different” (Altstedter, 
2017). Such assumptions, made from positions of power, have consequently translated into 
broader and seemingly more antiquated perceptions of cultural gender expectations and, resulted 
in the industry’s failure to recognize the shifting of consumer attitudes. 
 
Liability Concerns 
In addition to potentially gender-biased perceptions of consumer disinterest and an 
unwillingness to disturb an already lucrative hold on the contraceptive market, fears of liability 
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have contributed to pharmaceutical companies’ abandonment of new contraceptive development. 
The industry at large has an extensive and continuing record of litigation surrounding female 
contraception. In 2014, the pharmaceutical giant Merck & Co. agreed to pay $100 million to 
resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its 
intrauterine contraceptive device NuvaRing, including blood clots, strokes, and heart attacks. 
These cases addressed the experiences of approximately 3,800 women, including 83 reported 
deaths. Despite the legal action and ensuing settlement, the NuvaRing remained on the market, 
and in that same year, Merck made $723 million in profit from sales of it (Langhart, 2015). 
Merck’s settlement was not unusual; it came in the wake of similar lawsuits against female 
contraceptive makers. Its competitor, German pharmaceutical company Bayer AG paid $1.6 
billion over the prior two years to claimants against its oral contraceptive pills, Yaz and Yazmin, 
because of similar cardiovascular issues (Stanley, 2014). These recent settlements indicate that 
Pharma is willing to shell out money to keep its female contraceptives on the market, while 
simultaneously shying away from male contraceptive research for fear of similar legal troubles 
and financial risks. Moreover, although package inserts and company websites have been 
updated to contain adequate precautions, the continued acceptability of marketing products with 
such serious and demonstrated risks must be questioned, particularly in comparison to the 
delicate and wary treatment of male contraceptive candidates. 
 
A Double Standard 
Experimental male contraceptive compounds indeed have historically received 
considerably more caution in response to adverse effects. P​incus, while working on the female 
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pill in the 1950s, conducted a small-scale study testing the effects of Enovid on male patients in a 
mental hospital. Although now recognized as ethically questionable, this research demonstrated 
that Enovid had a “sterilizing” effect on the men. However, the men suffered severe side effects, 
including shrunken testicles. A similar clinical trial in the late 1950s was conducted on male 
prisoners with a combination of Enovid and testosterone preparations. Although the compounds 
fully inhibited sperm production, the subjects lost sexual desire and had difficulty getting 
erections and producing seminal fluid, and the attempt was deemed unsuccessful (May, 2010). 
While these adverse effects were justifiably unacceptable for widespread use, the immediate 
acknowledgment of these side effects stands in stark contrast to the skepticism with which 
Pincus treated women who reported equally unpleasant side effects during the testing of Enovid, 
which I will discuss shortly in greater detail. 
In the early ​1960s, scientists tested a potential contraceptive drug known as WIN 18,446 
in male prisoners. The compound, which is now understood to suppress spermatogenesis in the 
same way that Dr. Amory is now attempting to do, was found to lower sperm counts in the 
prisoner population without affecting libido (Amory & Bremner, 2016). The study’s promising 
results made national news (Tone, 2001). However, when clinical trials shifted to the general 
population, men experienced vomiting, sweating, headaches, and blurry vision (Kean, 2012). 
The drug was found to interfere with alcohol metabolism, causing men who drank alcohol to 
become violently ill, and was subsequently abandoned. Kean argues that “WIN 18,446 is a 
perfect example of why creating the male pill is so hard. It stopped sperm production in everyone 
who took it -- and it was reversible...Yet it failed anyway as a drug because of an arguably minor 
side effect” (2012). While it could be reasonably argued that this was more than a minor side 
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effect and would almost certainly have negatively impacted the drug’s acceptability to its 
prospective user population, negative alcohol interaction is in fact a common side effect in 
hundreds of modern medications used to treat dozens of conditions (NIAAA, n.d.). Addyi, a drug 
described as the female equivalent of Viagra that was approved by the FDA in 2015, has been 
shown to ​severely lower blood pressure in patients when drinking alcohol, possibly leading to 
loss of consciousness (Harrison, 2015). ​Thus, while the categorization of alcohol intolerance as a 
minor side effect may be debatable to some, it is not an uncommon one, nor has it prevented the 
regulatory approval of drugs such as Addyi. The rapid abandonment of WIN 18,446 suggested 
early on that male contraceptives would be held to high standards, in part because the calculus 
for male- and female-specific medication differs. 
Hormonal agents in particular, despite high levels of contraceptive success in a multitude 
of studies, have faced repeated challenges due to the presence of side effects deemed intolerable. 
A high-profile study led by the U.S. nonprofit group CONRAD and co-sponsored by the WHO 
was discontinued in 2011 despite promising data because “the risks to the study participants 
outweighed the potential benefits.” The study aimed to suppress spermatogenesis using 
coadministered injections of progestogen and testosterone every eight weeks in healthy men, 
aged 18-45 years. Behre et al. (2016) demonstrated reversible suppression of spermatogenesis in 
96% of continuing users, indicating a relatively high contraceptive efficacy in comparison with 
other reversible methods available for men, and even with hormonal methods for women. 
However, the study was terminated early following the recommendation of an external safety 
review committee monitoring the trial due to side effects deemed too severe to continue the 
therapy. Twenty out of the 320 participants had withdrawn from the study prior to its 
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termination. The adverse effects of concern to the committee were reports of pain at the injection 
site, increased libido, and a “relatively high” frequency of mood disorders. Additionally, one 
participant was diagnosed with depression (assessed by the researchers as probably related to the 
study regimen), one experienced an irregular heartbeat (assessed as possibly related), and one 
committed suicide (assessed as unrelated). Overall, more than a third of the adverse effects 
reported were concluded to be unrelated to the therapy, and 91% of adverse effects were 
classified as mild, while 99% were considered mild or moderate. Despite the side effects, 
feedback from the participants and their female partners demonstrated high rates of satisfaction, 
and more than 75% of participants said they would be willing to use the method if it came to 
market (Behre et al., 2016). Despite these high levels of efficacy and acceptability, recruitment 
of volunteers and administration of treatment were halted (Flynn, 2018). 
The early termination of this study proved to be inflammatory, sparking a feminist 
backlash and media uproar over perceived double standards in the development of 
contraceptives. The side effects reported in this study were noted to be similar to those that 
women experience on current forms of hormonal birth control. ​Fifty years after the original 
version of the pill was ​approved, current formulations of hormonal birth control use far fewer 
hormones than early versions, yet are still accompanied by a multitude of side effects which 
continue to be routinely tolerated in exchange for sexual and reproductive freedom.​ ​Possible side 
effects of ​the pill include nausea, headaches, breast pain, weight gain, mood changes, and 
changes in libido. Common side effects of the NuvaRing, a hormonal vaginal ring with 91% 
efficacy with typical use, include many of those associated with the pill, in addition to vaginal 
infections, discomfort, irritation, abdominal and menstrual pain, changes in hair growth, issues 
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with contact lenses, and decreased sex drive, among others (Planned Parenthood. (n.d. (c)). ​The 
seeming difference in the acceptability of side effects suggests that the burdens women must bear 
in ​exchange for their reproductive freedom are generally considered too much to expect men to 
deal with, whether or not men themselves would be willing to do so.  
Whereas mood disorders were one of the primary subjects of concern in this study,​ the 
relationship between available female hormonal contraception and mood disorders remains 
contested both in the scientific world and among the general public. While female users have 
reported mood-related symptoms for years, ​a definitive link has proven difficult to establish. 
Recently, a Danish study ​found a correlation between the use of hormonal birth control and 
diagnosis with clinical depression, suggesting a small but real increased risk (Skovlund et al., 
2016). The study has been praised as finally giving credibility to the lived experiences of 
women, although it has been critiqued by others. Jeffrey Jensen, a professor of Reproductive & 
Developmental Sciences at Oregon Health & Science University, contended that “women are 
more skeptical of using hormonal therapy than ever before. It's a tragedy of the riches. If you 
really want to be depressed, have an unintended pregnancy” (Haelle, 2016). This justification for 
the continued societal disregard for risks to women’s mental health stands in stark contrast to the 
concern shown in response to the male contraceptive study led by CONRAD. It reinforces the 
expectation that when it comes to a cost-benefit analysis between pregnancy and other 
drawbacks, women will make these trade-offs because they must. 
Some feminists thus maintain that male hormonal contraceptives with demonstrably high 
efficacy have been shelved at various stages of development and testing due to the continued 
existence of a gender bias toward standards of acceptability. Although many women are able to 
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use hormonal birth control without experiencing any significant issues, dissatisfaction with 
available methods is apparent from the rates at which women discontinue their use of these 
methods. The pill is the most common female contraceptive method in the United States, yet 
nearly a third of American users are so dissatisfied that they abandon it within the first year, 
usually because they are unable to tolerate the side effects (Khazan, 2015).  
Yet the abandonment of one method often only signifies the continued search for 
something more tolerable. In fact, nearly a third of women report having used five or more birth 
control methods (Daniels, Mosher, & Jones, 2013). The wide range of available female methods 
ensures that women who experience difficulties or complications are simply transitioned 
between drugs and devices: 
“I had a very difficult time with contraception. I found the coil horrendous--discontinued 
after 3 months due to heavy bleeding. I’ve tried 7 or 8 different brands of pills, but had to 
stop because they found pre-cancerous cells that required laser surgery. I was told I 
couldn’t use Norplant or injections either because of problems I’d had with the pill...so I 
became pregnant. Later I developed thrush from the cap.” (p. 82) 
The pill alone exists in a great enough variety that some women must go through a lengthy and 
difficult process of trial and error:  
“I went to my doctor each time with a problem with the pill, and each time she would 
give me another pill to try….She would say: ‘That’s all right. I know the answer. This 
one is much better.’” (Ringheim, 1996, p. 85) 
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Some women are thus kept on a prolonged rotation of medications, or are left settling for 
physically and mentally tolling regimens. More than two decades later, women are still 
recounting such experiences: 
“The cycle was always the same. Suffer on it for three months. Go to the doctor. Try 
something else. Every time I probed the doctors for more answers about how these drugs 
were different, they had zilch to say to me…. At 16, I realized for the first time that I was 
a complete hormonal guinea pig…. I'm sick of women being treated like lab rats. There's 
no way men would put up with trial and error when it comes to their hormones.” (Gould, 
2019) 
With such practices occurring regularly in reproductive health care, the repeated failure of 
studies such as that led by CONRAD may feel disheartening to many. However, while medical 
regulators have demonstrated a lower tolerance for adverse effects caused by experimental male 
contraceptives, a distinction must be made between minor side effects and serious complications.  
 
Safety and Regulation of Female Contraceptives 
The differences in the bar for what men and women are willing to or expected to tolerate, 
and the differences in the risk-benefit analysis for each, can be further examined by comparing 
current safety and acceptability standards in male contraceptive development to those used for 
early female oral contraceptives. The first birth control pill, marketed under the name Enovid, 
was approved by the FDA for contraceptive use in 1960. The gravity of its side effects, which 
became apparent in early testing of the drug, was minimized by both scientists and physicians for 
an extended period of time (Watkins, 1998). Seventeen percent of women in the first cohort of 
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the first large-scale clinical trials of Enovid, which took place in Puerto Rico, experienced 
significantly unpleasant side effects, causing a number of them to withdraw from the trials. 
Moreover, one woman died from congestive heart failure and another developed pulmonary 
tuberculosis, but researchers confidently concluded that “none of these effects could in any way 
be attributed” to the pill (Hartmann, 1995, p. 190). Dr. Edris Rice-Wray, who oversaw the trials, 
concluded that although the pill provided nearly 100% protection against unintended pregnancy, 
it caused “too many side reactions to be generally acceptable” (Tone, 2001, p. 223). Yet Pincus 
had little clinical empathy for what he regarded as hypochondria among the women in the trials, 
and dismissed her concerns (Planned Parenthood, 2015b). Claiming that many of the women’s 
symptoms were psychosomatic, he asserted that “most of them happen because women expect 
them to happen” (Tone, 2001, p. 233). When problems with the pill later gained attention, some 
expressed suspicions that “men’s scientific objectivity had been compromised by their sex” 
(Tone, 2001, p. 204). Indeed, Pincus’s response reflects an underlying disregard for the concerns 
of female patients that has never been uncommon in medicine. His response moreover illustrates 
that compromises were to be made to satisfy the exigent demands for a working female method. 
The willingness to make compromises for the sake of a reliable birth control method, 
both on the part of its makers and users, was demonstrated by the public response to the pill, 
particularly in the United States. Enovid was immediately embraced by hundreds of thousands of 
women as a marvel. As the Los Angeles Times wrote in 1967, “rarely in history has a change in 
mass behavior come so swifty. And never in history have so many healthy people taken such 
potent drugs month after month, year after year.” Yet, as was demonstrated in early trials, the 
benefits of the pill were double-edged. Some users experienced dizziness, weight gain, 
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headaches, mood changes, stomach pain, nausea, and vomiting. For some, the reactions were 
enough to discontinue the medication, while others found themselves willing to tolerate side 
effects in exchange for the ability to enjoy sex without constant worry about consequences, 
particularly at a time when abortion was either illegal or difficult to obtain (Marks, 2001). As one 
official of a New York clinic explained in 1967, “our patients are so glad to have something to 
keep them from getting pregnant that they rarely complain” (Los Angeles Times). From the start, 
the uniqueness of the female burden and the utter lack of alternative options inherently lowered 
the bar for what was deemed permissible.  
Lofty scientific, technological, and feminist ambitions may be used to explain the 
creation of an imperfect product, and the desperate need for a reliable contraceptive may be used 
to explain its mass acceptance among users. However, the subsequent and prolonged 
minimization of its considerable flaws remains difficult to justify. Enovid began its commercial 
life as a massive overdose, with 10 times the amount of hormones needed for effective 
contraception. The original high doses increased the likelihood and severity of side effects and 
the potential for rare but serious and occasionally fatal health problems such as blood clots, heart 
attack, and stroke. By 1962, Searle had received reports of several hundred cases of thrombosis 
and embolism associated with use of the pill, resulting in 11 deaths (Hartmann, 1995). However, 
in evaluating the pill’s safety, regulators were most concerned about its ability to prevent 
pregnancy because pregnancy and childbirth were inherently medically risky. In fact, the risk of 
thrombosis is higher among pregnant women than among combination hormonal contraceptive 
users. The FDA held that even if the pill caused these adverse events, the rate of them—1.3 out 
of 100,000 users—was much lower than the rate of women who would die from pregnancy 
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complications —36.9 out of 100,000 pregnant women (Planned Parenthood, 2015b). Other 
common pregnancy complications further include high blood pressure, preeclampsia, gestational 
diabetes, and depression (HHS Office on Women’s Health, n.d.). This judgment demonstrates 
once again the ways in which the cost-benefit analysis with regard to pregnancy that is unique to 
women has demanded that they assume certain risks, and has moreover qualified those risks as 
acceptable. 
Similar demands are made of today’s pill users, who continue to run a greater risk of 
circulatory disorders than nonusers. This risk is higher among women who smoke and are over 
the age of 35. The pill has moreover been found to increase a woman’s risk of breast cancer and 
liver tumors (Planned Parenthood, n.d. (a)). The NuvaRing may cause high blood sugar and high 
lipid levels in the blood (Merck & Co., Inc., n.d.). Rare but severe risks associated with the 
modern IUD include pelvic inflammatory disease, which can lead to infertility, and perforation 
of the uterus, which can potentially damage internal organs and require surgical removal. 
Pregnancy with an IUD, in its rare cases, is more likely to be an ectopic pregnancy, which 
implants outside of the uterus and can threaten the life of the mother (Planned Parenthood (n.d. 
(b)). Yet women routinely assume these health risks, and are permitted by their physicians to do 
so, because to many, the alternative is worse. Women’s bodies are the ones destined to endure 
the physical consequences if birth control fails. Thus, the cost-benefit analysis nearly always 
leans favorably toward the use of contraception, particularly with regard to temporal urgency. 
Low but actual risks of cancer or other chronic ​conditions might rationally be accepted by a 
woman for whom effective contraception is of great present value because of the health risks 
associated with pregnancy, labor, and delivery, or because of the personal, economic, and social 
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ramifications of an unwanted pregnancy. ​Some women may simply view this trade-off as an 
inevitable reality, whereas men face no similar dangers, no counterbalancing risk. The personal 
calculus of choice inherently differs between genders: preventing a pregnancy may be important 
to a man for a number of reasons, but not for his personal health or bodily integrity.  
It required nearly a decade after the pill’s initial approval, and uptake by millions of 
users, for scientists to prove the statistical link between thromboembolism and oral 
contraceptives, and to learn that much lower doses were just as effective at preventing 
pregnancy. Even then, the FDA was slow to act, concluding in 1969—after this link was 
established—that the pill’s benefits sufficiently outweighed the risks (Hartmann, 1995). In 1970, 
the U.S. Senate held hearings on the safety of the pill and the lack of adequate information on the 
relative risks and benefits of its use, during which not a single woman was asked to testify before 
the all-male committee. It was not until 1978 that the FDA required manufacturers to include a 
comprehensive informational pamphlet in every contraceptive package. Over time, lower-dose 
formulations were brought to market, yet it was not until 1988, after pressure from the FDA, that 
manufacturers removed high-dose oral contraceptives from the market (Watkins, 1998). 
The slow regulatory and industry responses to the early pill’s flaws fostered growing 
concerns among women’s health advocates about the standards used to judge the safety of 
products under development, as well as the role of science and technology organizations and 
pharmaceutical companies in women’s bodies and rights. As women were forced to balance the 
freedom from pregnancy against the risks the pill posed to their health, “the swallowing of a pill 
represented not so much a liberty as the imposition of a control over their bodies by the medical 
profession and the pharmaceutical industry” (Marks, 2001, p. 186). The power of the pill as a 
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liberating technology was diminished as women began to question why men controlled these 
fields, and why women’s health interests were suffering as a result. Some wrote letters to Pincus, 
asking him to direct attention toward men instead (Tone, 2001). The public response to the 
injustices of the pill became as much a general indictment of sexism in American society as it 
was an increased scrutiny of the medical and scientific establishments. 
Yet while some women became increasingly disillusioned with the pill, it remained a 
powerful and popular technology throughout this period of medical uncertainty. After a brief 
drop in users following the Senate hearings in 1970, prescription rates for oral contraceptives 
rebounded in the U.S. and the number of users continued to rise. In many ways this has always 
been the relationship between women and contraceptive technology. ​One pill user reported: “I 
don’t care if you promise me cancer in five years, I’m staying on the pill. At least I’ll enjoy the 
five years I have left” (Tone, 2001, p. 245). The coexisting views of contraceptive technologies 
as “among the great liberators of our time” and “among the great oppressors of our time” aptly 
illustrate the complexity of their meaning in our society. As Ann Saetnan asks, “How can a 
single technological artifact...have such manifold and contradictory impacts?” (2000, p. 2). 
These complexities must be kept in mind when envisioning the integration of something new. 
Still, from the perspective of the 21st century, it is difficult to imagine how and why the 
original formulation of Enovid was kept on the market for so long. The extreme lapse in 
regulatory judgment that allowed the extended use of a drug for which red flags had been so 
blatantly raised can, in part, be explained by putting it in the context of its time. The pill arrived 
at a time before several major crises shook public faith in medicine, a time when ​“it seemed that 
medical research could do no wrong,” ​when new drugs were rapidly being introduced: 
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“pharmaceutical companies, the media, and the public proclaimed and accepted the benefits of 
the postwar chemotherapeutic revolution. Every problem, be it a medical one or a social 
one...seemed amenable to a ‘technological fix’” ​(May, 2010, p. 126; ​Djerassi, 1994, p. 102). The 
development of the pill moreover preceded a vast overhaul of FDA regulation that led to stricter 
standards of safety and more rigorous clinical trial requirements. ​At the time of Enovid’s 
approval, the scope of FDA authority had not changed since the passage of the 1938 Food, Drug, 
and Cosmetic Act, which had imposed the first requirement of safety on drug development in 
order to regulate the medical market.​ Ethical standards in research also differed from those 
established today, and the use of human subjects was poorly regulated. In the 1950s, there were 
no fixed rules as to what constituted an appropriate sample size to test a new drug, and trials of 
the pill generally adhered to the standards of the time. In the wake of the “pill crisis,” the FDA 
imposed tougher standards, requiring larger data samples and better regulation of 
experimentation on human subjects (Tone, 2001). 
After the introduction of Enovid, another medical disaster contributed to the end of the 
postwar faith in medical technology and a growing suspicion of the pharmaceutical industry. In 
the early 1970s, the Dalkon Shield IUD became another example of a product through which 
women were exposed to unnecessary risks in the name of corporate profit, and to which the 
regulatory response was appallingly absent. At this point, the FDA still had limited authority 
over the medical device industry. The pharmaceutical company A. H. Robins aggressively 
advertised its IUD for several years while downplaying or ignoring user reports of terrible 
complications. The device caused over 200,000 infections, miscarriages, septic abortions, and 
hysterectomies, led to an untold number of birth defects, and was tied to at least 18 deaths (Tone, 
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2001). Hundreds of thousands of women sued the makers for knowingly marketing a product 
that increased the potential of life-threatening complications, eventually bankrupting the 
company in 1985 (Tone, 2001). The case caused considerable negative media attention and 
public skepticism about IUDs, casting a shadow over subsequent research in the field and 
catalyzing legislation authorizing the FDA to regulate medical devices ranging from IUDs to 
pacemakers (Beaton, 2017). Pharmaceutical disasters such as the Dalkon Shield and thalidomide, 
a sedative that was marketed in the 1950s and early 1960s as treatment for morning sickness in 
pregnant women and caused the births of thousands of babies with debilitating malformations, 
contributed significantly to the increased stringency of drug and device regulation in the decades 
following (Vargesson, 2015). 
Because of the major changes that have occurred between the introduction of the pill and 
the current generation of products under development, it is difficult to compare standards across 
time. In some ways, the lessons learned from the turbulent history of female oral contraception 
changed the process of future contraceptive endeavors for the better, ensuring that more stringent 
standards were established and allowing for the more cautious approval process that exists today. 
Additionally, as the field progresses, the more that is understood about the human reproductive 
system and about hormonal manipulation, the more there is to account for.  Djerassi argues that 
the special requirements that have been imposed in the case of drugs used for fertility control are 
“understandable and justified,” as “a response to our gradually increasing knowledge of human 
reproductive physiology in general, our accumulated experience with oral contraceptives in 
particular, and especially the surprisingly rapid acceptance by so many women of these new birth 
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control agents” (1994, p. 41). The benefit of past experience with female methods has raised 
demands for safety and testing of side effects.  
However, at the same time, it is possible that excessive scrutiny of male alternatives has 
become a constraint on progress. While caution is necessary, “no drug can be totally effective 
and completely safe, and no agency of government can guarantee that it will be” (Djerassi, 1994, 
p. 49). Past experiences, as Darroch suggests, have also “hopefully lowered expectations that a 
new method will be ‘perfect’ and suitable for everyone throughout their reproductive lives” 
(2000). Darroch’s point highlights a key challenge faced by researchers and feminists alike in 
judging the acceptability of male methods in which safety is prioritized and standards are 
realistic. Djerassi worries that the risks and costs of developing such agents have escalated to 
such an extent that it is unlikely that the traditional course of drug development will lead rapidly 
to the creation of fundamentally new contraceptive agents: “if the present climate and 
requirements had prevailed in 1955, oral contraceptive steroids would still have been a 
laboratory curiosity in 1970” (1994, p. 41).  
 
The Funding Dilemma  
The medical mishaps of the 1960s and 1970s changed the landscape of pharmaceutical 
development. Carl Djerassi identified three reasons for Big Pharma's flight from contraceptive 
research: (1) increased regulatory stringency, which greatly expanded the time and expense of 
developing new products; (2) a negative portrayal of the industry by the media in the wake of 
inquiries into the safety of the pill and the subsequent Dalkon Shield IUD disaster; and (3) the 
increasingly litigious nature of American society, as the courts became the place to seek 
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restitution for injuries or diseases attributed to drugs, medical devices, and other substances 
(Watkins, 2012). Leading scientists left the field, accompanied by a growing “estrangement of of 
academic and government scientists from those who work in industrial laboratories” (Djerassi, 
1994, p. 70). Pharmaceutical firms scrapped or tabled promising projects as they swapped birth 
control initiatives for less risky ventures. In 1970, 13 major drug firms were actively pursuing 
contraceptive research and development, of which nine were American; by 1987, there were only 
four, with just one in the U.S. (Watkins, 2012). As was demonstrated by the history of the female 
oral contraceptive, a drug’s side effects may take years to materialize to their full extent, and 
long-term safety cannot be put beyond doubt prior to its entrance into the market. Due to an 
acquired wariness of risk, ​pharmaceutical leaders have thus begun to shy away from such 
ventures, shifting their focus to less controversial projects. 
Without the backing or resources of the powerful pharmaceutical industry, researchers 
have been left to find other sources of funding. Male contraceptive research continues to be 
funded by government agencies and by nonprofit organizations such as the Bill & Melinda Gates 
Foundation. Yet the industry absence is still felt, for it possesses a “unique ability to organize, 
stimulate, and finance multidisciplinary R&D covering the entire gamut of the scientific 
disciplines required in converting a laboratory discovery into an practical drug” (Djerassi, 1994, 
p. 41). Indeed, the power afforded to Big Pharma by virtue of its wealth should not be 
underestimated. In 2017, the top 10 global pharmaceutical companies all generated more than 
$20 billion in pharmaceutical revenue alone, with the top company earning more than $52 billion 
(Statista, 2019). While “ideas for innovative drugs may come from outside the 
industry….Universities can’t put pills in bottles and sell them” (Angell, 2004, p. 71).  
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Small biotechnology enterprises have begun to pick up the slack in this field, yet lack the 
resources of larger companies. When the hormonal study led by CONRAD was terminated early, 
the research team did not have adequate funding to test another formulation (Flynn, 2018). The 
“clean sheets pill,” project has similarly been stalled in the past several years due to lack of 
funding for continued research (Parsemus Foundation, n.d. (b)). ​The Parsemus Foundation is 
developing Vasalgel as a social venture, and is committed to making the treatment affordable 
and widely available (Parsemus Foundation, 2018). The foundation plans to sell Vasalgel for 
close to cost in low-income countries, and make it affordable to those at every income level in 
the U.S. The product could potentially be sold at $10 to $20 per person in low- and 
middle-income countries, and $400 to $600 per person in wealthier markets, according to Elaine 
Lissner, the foundation’s founder (Altstedter, 2017). However, the foundation states that it does 
not have enough funding to finish the project. It has conducted fundraising campaigns and 
sought wealthy “social investors” to help support the preclinical animal studies that are paving 
the way for the first human trial. Lissner estimates that should the FDA permit clinical trials to 
take place in humans, this next step will cost millions of dollars (Parsemus Foundation, ​(n.d. (a)​). 
However, Lissner has lamented that the response from representatives of the Bill & Melinda 
Gates Foundation has been lukewarm, as its primary focus has instead been on contraceptive 
options for women in developing countries. In 2016, the foundation gave $600,000 worth of 
awards for research into male birth control. By comparison, it spent $147.9 million on family 
planning efforts aimed at women (Mullin, 2017). While these efforts remain crucial to meeting 
unmet need, particularly in developing countries, this imbalance in the distribution of resources 
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reflects the perpetuation of ingrained social priorities in which we fail to recognize areas of great 
potential to expand overall involvement in and access to family planning. 
 
Changing The Market Mentality 
In many ways, marketing decisions, rather than scientific innovations, have guided the 
development and availability of next-generation contraceptive products. The body of knowledge 
in the reproductive sciences is fairly expansive, and promising technologies are in development, 
but the continued testing and subsequent availability of these technologies have been delayed by 
the failure to commit sufficient monetary resources. Pharmaceutical companies have intimated 
that they require greater assurance that such a technology will succeed—that is, that it will work 
and that men will use it. However, The continued efforts of non-industry scientists and 
benefactors suggests that while Big Pharma has been discouraged by heightened scrutiny of new 
pharmaceuticals and uncertainty of profit, there remain a number of groups championing the 
male contraceptive objective. The scientists behind the DMAU pill trial, for example, have 
worked in the field for years and note welcome and unprecedented energy around this research 
today, with public interest providing a positive momentum that did not seem to exist 15 years 
ago (Sifferlin, 2018). However, while great strides have been made within the past decade, even 
the most advanced of these options is likely at least a decade away from commercial availability. 
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Conclusion 
Both women and men think of reproduction in terms of women’s bodies and of birth 
control as a woman’s responsibility, and this idea has been perpetuated by social and cultural 
beliefs and materialized in available technologies. ​Modern female contraception has provided an 
important tool for millions of women to effectively control their own fertility, freeing them from 
fears of pregnancy and constant childbearing and enabling them to take advantage of expanding 
opportunities for education, employment, and participation in public life. Although modern 
contraceptive formulations reflect improvements from more than half a century of extensive 
research, the trade-offs associated with available female contraceptives indicate that there still 
exists demand for better and alternative options, and serve to highlight the need for new male 
contraceptives. To this end​, the introduction of more sophisticated and varied options for male 
contraception must become a more prominent objective in research, policy-making, and the 
commercial realm.  
As I have demonstrated, the relative neglect of this objective is the product of a great 
number of social, cultural, scientific, and economic factors, some more direct and intentional, 
others more underlying or incidental. However, “to recognize the political dimensions in the 
shapes of technology does not require that we look for conscious conspiracies or malicious 
intentions” (Winner,  1986, p. 25). To understand why the development of contraceptive 
technology has unfolded as it has, and to envision ways to change its course, it is essential to 
recognize the reciprocal ways in which this technology has shaped our world, and in which the 
the world it created has dictated the subsequent trajectory of its development. Winner describes 
the production of technology as “an ongoing social process in which scientific knowledge, 
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technological invention, and corporate profit reinforce each other in deeply entrenched patterns, 
patterns that bear the unmistakable stamp of political and economic power” (1986, p. 27). In 
recognizing those deeply entrenched patterns, in identifying the sources of power, we can hope 
to dismantle those patterns and harness the necessary power. 
The birth of the pill and the subsequent history of female contraceptives reveal much 
about the negotiations involved in bringing technological ambitions to fruition, and how the use 
and meaning of new technology are negotiated in society. The pill generated great interest 
among the medical profession, pharmaceutical industry, federal government, family planning 
organizations, feminist advocates, the media, and the public. The missions of these groups 
sometimes conflicted as their interpretations of the meaning of the pill differed, yet ultimately 
the amalgamation of their enthusiasm, power, and resources provided the impetus necessary to 
make modern female contraception a technological reality. By contrast, the search for male birth 
control has thus far lacked attention, social impetus, legitimacy, or resources comparable to those 
that propelled forward the creation of the pill.  
In some ways the absence of male contraceptives is a sustained response to the history of 
female contraception. The pill played a key role in the movement for reproductive rights, the 
achievement of standards in medical research and drug development, and establishment of 
requirements surrounding consumer safety and access to knowledge of pharmaceutical risks and 
side effects. However, the gains made laboriously through the creation and gradual improvement 
of female contraceptives have perhaps simultaneously hindered any hopes for a male alternative. 
Perhaps, in part, we fail to recognize just how powerful the backlash against the pill was in in 
shaping future research and popular conceptions of drug safety. Yet there does appear to exist an 
 
 
 
         92  
fundamental double standard in the ways in which male and female health is envisioned and 
valued in society. Female suffering has been consistently overlooked or minimized; male dignity 
has been grounded in the preservation of male bodily function in a way that is not for females; 
and the women have been saddled with the burdens of pregnancy in a way that men have never 
been, so that the expectation of physical sacrifice in the use of contraceptive technology differs 
wildly for each.  
The slow progress of male contraceptive efforts highlights the importance of recognizing 
what is scientifically feasible and approaching continued challenges realistically, particularly if 
pharmaceutical firms are to be convinced that this technology has the ability to ​attract the proper 
social and market interests​. With this in mind, discussions surrounding the widespread 
introduction of male contraception and success among potential users must address the need for a 
balance between shaping technology and its users’ expectations. Ringheim (1993) suggests that 
while “it is more desirable (and easier) to modify technology to suit people than to attempt to 
modify people to suit technology...flexibility must come from both sides” (p. 93). He argues 
further that “while biomedical scientists have been convinced that development of an 
unacceptable method is pointless, potential users, service providers, and policymakers have 
realized at the same time the unlikelihood that science will produce an ‘ideal’ contraceptive that 
is...free of all side effects and 100 percent effective” (Ringheim, 1993, p. 93). It will therefore be 
necessary to adjust producer and consumer expectations of a perfect contraceptive method, with 
an emphasis on comparison to the historical and current contraceptive experiences of women. 
Effective adoption of a new male contraceptive will have as much to do with reorienting 
cultural definitions of masculinity as with fashioning and disseminating the product itself. It must 
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also entail the reconstruction of social and institutional frameworks that encourage 
gender-specific contraceptive roles. ​The prevailing assumption has been that family planning is 
both a woman’s right and responsibility, and that men are not interested in further involvement. 
There are good reasons why family planning programs and reproductive health initiatives have 
focused on women, but the exclusion of men from these efforts has not only impaired men’s 
ability to participate more actively in contraception, it has ultimately hindered the goals of 
gender equality. 
Long-acting, reversible male contraception has the potential to be a disruptive 
technology, one which could radically change society. Ultimately, this objective is achievable, 
yet it faces a number of extra-scientific obstacles. The continued lack of male contraceptive 
technology has much to do with the insidious consequences of both the patriarchal and 
capitalistic ideologies that prevail in our society. Progress has been hindered by regulatory 
hesitance, motivations of profit, and the misguided notion that we live in a society in which 
current practices and ideas are too ingrained to be conducive to technological change. The failure 
of this technology to emerge is a result of conflicting interpretations of both the importance and 
viability of such a technology, such that new male contraceptives have simply not been 
prioritized. 
Technology succeeds with viable networks of collaboration, and with social impetus 
generated through perceived social need. We must create new models of collaboration in which 
all parties view their engagement and investment as winning propositions. This represents one of 
the greatest challenges to bringing a new male contraceptive method from laboratory to market. 
The fulfillment of this objective requires partnerships between government, academia, 
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family-planning services, non-profits, and industry to identify the best candidates for testing, 
approval, marketing, implementation, and accessibility. It moreover requires small- and 
large-scale advocacy, new educational focuses, and more frequent dialogues in an effort to 
promote the interest in and need for new male contraceptive options. There is great potential to 
be unlocked. 
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